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1 Introduction  
Background 
Following recommendations laid down by a consensus conference in 1986, the policy of the 
Norwegian government has been to offer a routine ultrasound scan to all pregnant women at 
18 weeks of gestation, i.e. in the second trimester (weeks 14-27) of pregnancy (1). This form 
of antenatal screening is also provided in other European countries, though several countries 
have gone further and now offer universal screening in the first trimester (weeks 1-13), 
between the 11th and 13th week of gestation, as well as in the second (2).  In 2006, the 
Norwegian Directorate for Health contemplated a revision of its antenatal care guidelines, and 
in the process, sought to determine whether an expansion of the programme to incorporate 
universal first trimester screening would be a rational step with regard to the anticipated extra 
benefits and costs. Except for a relatively small patient co-payment charge, antenatal 
screening is publicly financed as is the case with most other health services. Norway has 
however, a small but thriving private health care sector, and first trimester ultrasound 
scanning has been offered by private providers in recent years.   
 
The are many potential benefits of antenatal ultrasound screening and some of them are 
undoubtedly controversial. The information gained from a scan may, depending on its timing, 
assist in determining the pregnancy term, the number of foetuses in the uterus, the location of 
the placenta and the condition of the foetus. If the foetus is found to suffer from a particular 
disease, it may sometimes be treated prior to birth (3). Invariably however, ultrasound 
scanning in pregnancy is often associated with the detection of foetal anomalies or defects, 
such as Down syndrome, congenital heart defects or neural tube defects. The detection can in 
some cases lead to the pregnancy being terminated, whilst in other cases it may prepare the 
parents for a life with a child who may require more attention and care than others. This 
provision of information may be considered beneficial, however one may choose to act upon 
it, although it also invites an active decision which could induce negative feelings. On the 
other hand, the potential stress and anxiety involved in the screening and diagnostic process 
may be viewed as disadvantageous (4). This study will focus on two of the most important 
anomalies, at least in terms of the attention they are given in the literature: Down syndrome 















Down syndrome, also known as trisomy 21, is caused by a fertilized egg having three copies 
of chromosome 21 rather than two. The condition may be mild or severe, but is generally 
characterized by slower than normal physical and mental development.(5). The disease is 
associated with mild to moderate mental retardation, though many children with Down are 
able to lead a close to normal life, with varying degrees of assistance required, for example in 
the form of speech or physical therapy or extra tuition.   
 
The prevalence of Down syndrome in Norway was found by Melve and colleagues (6) to be 
2.0 per 1 000 among the 288 213 births and terminations recorded in the Medical Birth 
Registry of Norway in the period 2001-2005. Risk tends to increase with maternal age (7;8) 
and the results of screening studies will therefore be dependent upon the age composition of 
the population studied. In Norway the watershed high-risk mark in terms of age stated in 
guidelines for antenatal care is 38, whilst in other countries it may be 35 (reference).  
 
The screening alternatives relevant to the present analysis are as follows. In the first trimester, 
measurement of nuchal translucency in ultrasound screening is, together with maternal age,  
employed to calculate the risk of Down syndrome. Nuchal translucency (NT) refers to the 
thickness of the fluid collected behind the neck of the foetus (reference BMJ), which is only 
present for a short time, between weeks 10 and 14 of gestation, and may signal the presence 
of disease or foetal immobility. In addition to ultrasound with NT, a blood sample can be 
taken to test for two serum hormone markers; human chorionic gonadotrophin (hCG) and 
pregnancy-associated plasma protein (PAPP-A) which are indicative of chromosomal defects 
such as Down syndrome. Together, the ultrasound and the serum test are sometimes referred 
to as the combined test or the double test. If the risk of Down syndrome is considered to be 
significantly large, the invasive follow-up test known as chorionic villus sampling is 
warranted. In the second trimester routine ultrasound scan, the operator investigates so-called 
soft markers, which are minor anatomical variations that, combined with maternal age, are 
used to assess the risk of chromosomal anomalies (9). If the risk is deemed to be high, 














Serious Congenital Heart Defects 
Serious, major or critical congenital heart disease (SCHD) differs from other congenital heart 
defects by being associated with high mortality rates, although these can sometimes be 
treated, either in vitro or with long-term follow-up (10). The incidence of these conditions 
accounts for  around half of all detected cases of congenital heart defects (10).  They may 
involve defects such as complete transposition of the great arteries or hypoplastic left heart 
(10). According to a study from Northern Norway, 4 out of 23 infants with SCHD died soon 
after birth, which represents a mortality of 17.4% (11). The prevalence is estimated to be 
around 4 per 1000 live births (10-12). The risk of SCHD seems to be positively related to 
maternal age (13)  
 
The ultrasound screening alternatives for SCHD considered here involve nuchal translucency 
measurement in the first trimester. This is an indicator of serious congenital heart defects as 
well as Down syndrome (12), and the two conditions may sometimes be present 
simultaneously. However, if chromosomal anomalies are ruled out, the relevant follow-up 
diagnostic tests are not invasive, but simply involve referral to a specialist for a more 
thorough ultrasound scan. The same applies to the routine scan in the second trimester.  
Suspected SCHD in the second trimester can be investigated in an ultrasound scan using the 
so-called four-chamber view of the foetus’ heart (12). Visualisation of the ventricular outflow 
tracts may enhance diagnostic precision (10).  
Current practice 
The potential number of ultrasound scans per year is determined by the number of 
pregnancies, which in turn may be estimated by the number of births. There is of course, some 
overlap here given that a pregnancy may start in a given year and end in another. In addition, 
it is likely that a number of early miscarriages go unrecorded. The number of voluntary 
abortions was14,132 in 2006  (14), 95 % of which took place before the 12th week of 
gestation.  The number of births in Norway has in the decade from 1996 to 2006 been 










































Source: Statistics Norway, 2007 
 
All pregnant women are offered a routine ultrasound scan between the 17th and the 19th week 
of gestation. This most often takes place in a hospital outpatient department, but may also be 
carried out in primary care. The purpose is to obtain information with regard to the foetal age 
to estimate the term, the foetus’s anatomy and development, the number of foetuses, and the 
location of the placenta (15). Where an anomaly is suspected, the pregnant woman is referred 
to specialists for diagnostic testing at one of the major hospitals in Norway. 
 
Current guidelines however do allow for ultrasound in the first trimester to be offered to a 
select group of pregnant women, but this is not considered part of the routine ultrasound 
programme, but rather a part of a genetic counselling and foetal diagnostics service  (7;15;16). 
To be eligible, pregnant women have to satisfy one or more of the following criteria: 
 
• 38 or older at the end of their term. 
• Either themselves or their partner 
o have conceived a child with a serious congenital disease or anomaly (for 
example chromosomal disorders) 
o have a documented increased risk for serious foetal disorders  
• Use medications which may harm the foetus 












• Who find themselves in a difficult life situation and who maintain that they will not be 
able to cope with the extra burden a sick or strongly handicapped child might pose. 
 
The latest figures available as to the number of women who fall into this category are from 
2000 (17) and suggest some 5 000 women per year.  
 
According to current policy, Norwegian pregnant women are therefore allocated to one of two 
paths described as “Routine” or “High risk” in the flowchart below. If a strategy of universal 
scanning in the first trimester is implemented, all women will follow the “high risk” path. The 
Norwegian health authorities have only considered an extension of the screening programme 
to include a service of universal screening in the first trimester. The current practice of 
screening in the second trimester is not challenged, at least not from an official position. The 
strategies compared here therefore only differ in terms of the approach taken in the first 













































The primary objective of this analysis is to model the costs, outcomes (anomaly detected) and 
the incremental cost-effectiveness in terms of cost per additional anomaly detected of 
alternative screening policies, from both the health care and societal perspective. The 
anomalies incorporated here are Down syndrome and serious congenital heart defects. 
 
Assuming 60,000 births annually, the three strategies under investigation are as follows: 
 
Current: Current practice in the first trimester, i.e. ultrasound screening and follow-up 
diagnostic testing offered to a “high risk” group (n=5 000), but no screening in the low-risk 



































Comprehensive: All pregnant women (n=60 000) are offered routine ultrasound screening and 
follow-up diagnostics in both the first and the second trimester. 
 
Combined: As in the comprehensive strategy (n=60 000), but with the addition of two serum 
hormone tests combined with ultrasound screening in the first trimester, and regular routine 
screening in the second. The serum hormone tests, hCG and PAPP-A, are only considered as 
determinants of the risk of Down syndrome and will therefore not affect the performance of 
the test for SCHD. 
 















2 Literature review 
In the review of the literature, it seems reasonable to start by looking at the definition of 
screening in general and antenatal screening in particular, before moving on to examine the 
potential harms and benefits. Finally, a presentation is given of how screening programmes 
might be evaluated and of some of the challenges that arise in terms of the design and 
interpretation of such evaluations. 
Screening: Definitions and objectives 
Screening in general 
Screening is, in the stripped-down definition of Merriam-Webster’s medical dictionary “to 
test or examine for the presence of something (such as a disease)” (18).  It is probably unfair 
to accuse a renowned medical dictionary of being too concise, but in this case such a 
definition would not suffice: What, for example, would be the difference between a normal 
medical examination in which blood pressure and urine samples are taken, and a screening 
programme for hypertension or proteinuria? Thankfully, the literature on screening, why it is 
done, to whom, by whom and not least at what time, is nothing if not extensive. There seems 
a general consensus however, that the objective of screening is to systematically separate 
those afflicted – or with a high risk of becoming afflicted – from those who are not, so that 
some form of health intervention targeted at the former group might be planned, and resources 
set aside  (19). Ideally, this would take place in a situation where the screened individuals are 
still in a curable stage of disease (20). 
 
For screening to make any sense, it should be performed on a relatively large scale, in a 
systematic fashion, and on individuals who appear to be healthy. The process is therefore 
often understood as a public health intervention, which suggests that it has to be a co-
ordinated effort, either by government or some other sizeable organisation with the public 
interest in mind, serving the purpose of identifying those who already are - or those who are 
likely to become - sick (21). Governments may therefore initiate screening programmes and 
actively encourage parts of the population to enrol, and also screen selected segments of 
society routinely while in school or in the armed forces. The benefits of screening were first 
demonstrated after the Second World War, when mass miniature radiography was used to 












ensured that a number of mass screening programmes could be implemented in the post-war 
period (20). Holland & Stewart (22) report that the possible economic implications of 
screening were observed as early as the 1900s, when Morris Cullen, medical director of the 
Kaiser Programme health maintenance organisation, suggested that regular screening could 
reduce costs and utilisation of health services in the United States. However, the authors also 
refer to the popular screening programme against cervical cancer in the UK in the 1960s and 
1970s, which involved a simple smear test but nevertheless placed a huge strain on cytology 
laboratories, as an example of a waste of public resources. That screening is often undertaken 
by governments does not imply that people might not on an individual basis decide to test 
themselves in large numbers even if there is no co-ordinated effort or encouragement from the 
authorities. Such behaviour, sometimes referred to as on-demand testing, is therefore not 
necessarily screening in the traditional sense (23). One could argue however, that if sufficient 
on-demand testing takes place, whether it be in a public sector health service setting, a private 
clinic (24) or even at home (25), this would constitute a de facto screening programme in the 
sense that it would lead to a change in demand for health treatment or prevention services that 
might not have occurred in the absence of mass testing. Although not a public health 
intervention, it might still be analysed as if it were. Not yet a common household appliance, 
the development in ultrasound technology has nevertheless been formidable, and obstetric 
ultrasound services are offered privately in a number of countries. Some are sceptical to the 
commercialisation of such services, on the grounds of inequality of access (26) or the lack of 
a cohesive system to care for those who test positive for some condition (24) or to allow for 
sufficient resources to be diverted to treatment. That is not to say that governments may be the 
more efficient provider; as Holland & Stewart (22) point out, screening may sometimes be 
carried out more for political  – to show that the government cares – rather than for medical 
reasons . Moreover, mistakes are likely to be made regardless of who commissioned the 
screening test, as long as the test itself is imperfect.  
 
A screening test is intended to yield either a positive or negative result, but it is the test’s 
performance which determines the degree to which the result can be trusted. The test therefore 
does not offer a conclusive answer, but rather an indication of whether or not a condition is 
present or not. Individuals may be referred for further testing with a so-called “gold-standard” 
test but even such tests do not necessarily provide confirmation (21). The test performance is 
usually measured in terms of sensitivity and specificity. The former is a fraction denoting the 











condition, hence “picking out” those who are actually affected. The latter measures the 
number of people who test negative out of those who do not have the disease. Particularly in 
the case of ultrasound scanning, these indicators are products of both the technical standard of 
the test as well as the skill level of the ultrasound operator. Ideally both indicators should be 
high, to minimise the number of false positives (one minus specificity) and false negatives 
(one minus sensitivity). False positive cases involve unnecessary and sometimes irreversible 
health interventions, as well as stress and anxiety (27), whilst false negative cases mean that 
treatment of a condition will be delayed or not occur at all, there may also be negative 
psychological effects and the public confidence in the screening test may be affected 
negatively (28).  
Antenatal screening 
Antenatal or prenatal screening is simply screening that takes place at some point(s) between 
conception and birth. It could be argued that antenatal screening may take place even prior to 
conception to the extent that couples who see themselves as “high-risk” seek genetic 
counselling prior to deciding to have a baby (22). Ultrasound scanning is a procedure used in 
antenatal screening involving a non-invasive diagnostic imaging device with a so-called 
transducer scanner being moved either across the abdomen or through the vagina to produce 
radio wave images of the foetus onto a screen. The first two-dimensional ultrasound machine 
was built in the UK in 1956 (29). The original purpose was to determine gestational age, the 
location of the placenta and the presence of multiple pregnancies. As the technology 
developed, the scanners could also be used to spot certain antenatal anomalies. Routine 
scanning in the second trimester (week 18) was introduced as a health service paid for by the 
public purse in countries across Western Europe in the 1980s (22). Since then, some countries 
have extended the coverage to include a scan in the first trimester. A survey of policies with 
regard to routine ultrasound scanning in 18 European countries in 2004, conducted by Boyd 
(2), showed that 4 countries, Sweden, Denmark and England/Wales among them, had 
implemented a policy of two scans per pregnancy. Five countries had 3 scans, including 
France, Germany and even predominantly Catholic Italy. Ireland and Spain had none and so, 
perhaps surprisingly, did the liberally-inclined Dutch. Norway maintains a general policy of 
offering a free ultrasound examination to all pregnant women in the second trimester, and has 












The perceived benefits and harms of screening 
As has been noted, it is usually the case that a screening test cannot entirely rule in or rule out 
a condition, but merely suggest a change in likelihood of its presence. The benefits - and 
disadvantages or harms – associated with a screening test will thus to a great extent depend on 
its performance characteristics (sensitivity and specificity) but also on external factors such as 
the prevalence of  the condition(s) in question and the treatment options available if a test is 
positive (22).  The original purpose of ultrasound screening was to assist in determining the 
term date, the position of the placenta and existence of multiple pregnancies. It is hardly 
controversial to claim that the provision of such information to obstetricians and parents 
would help in the planning of the pregnancy (31) and the neonatal period, especially if a 
difficult delivery is anticipated. Today however, the information provided by ultrasound 
scanning may be used for more advanced purposes, namely as visual assistance in operations 
upon a foetus before birth. The first such procedure was carried out in 1982 for obstructive 
uropathy. Although the operation was technically a success, the patient unfortunately died 
after birth due to other conditions (32). Improved ultrasound technology, along with the 
advance of antenatal surgery techniques, have brought about rapid advances in the field of 
foetal medicine, and the option of in vitro treatment for some conditions prior to birth (3). The 
last two decades have, according to Kumar & O’Brien (32), seen antenatal surgical 
interventions for conditions besides obstructive uropathy such as spina bifida, congenital 
diaphragmatic hernia and cystic adenomatoid. The procedures do not necessarily have to take 
place prior to birth: Andrews et al. (33) refer to a condition in which antenatal diagnosis is 
deemed particularly important with regard to the planning of the birth and complicated 
neonatal reconstructive surgery; hypoplastic left heart syndrome. Ultrasound scanning may 
hence lead to an improved prognosis for some foetuses since they may receive treatment 
sooner rather than later, and the treatment may be of a less radical kind than would otherwise 
have been required (34). On the other hand, considering the worst case scenario of a lethal 
malformation being found in the foetus, a missing brain for example, ultrasound offers the 
chance to terminate the pregnancy sooner rather than the mother having to proceed to give 
birth to a stillborn child. If a non-lethal but serious malformation is found, late abortion may 
be an option, but there is also an opportunity given to prepare for a challenging but potentially 












A negative test will in most cases provide reassurance to parents.  The flipside of the coin is 
the fact that, due to the fallibility of the test, there is a risk of the test result being wrong, i.e. 
rendering a false negative case. The need for reassurance is after all, the prime reason why 
women with normal risk profiles desire ultrasound testing, or at least this is the case in 
Denmark, given the conclusions of a survey of 370 pregnant women from that country 
published in 2006 (35). It also seems that the desire for a picture of the baby is a factor, 
especially among women pregnant for the first time and those from lower income groups. 
However, there might still be some degree of stress and anxiety related to the perceived lack 
of safety of the scan itself (36). Although it has been suggested that exposure to diagnostic 
ultrasound during pregnancy may be associated with reduced birth weight and childhood 
malignancies or neurological disorders, no evidence of this has been found. The evidence is 
somewhat stronger with regard to the proposed link between antenatal ultrasound exposure 
and left-handedness (36). It is hardly the prospect of a left-handed child however, that is the 
source of the anxiety involved in the screening process, but rather the fear of a lethal or 
serious anomaly. This may arise before the screening takes place, at the screening test and at 
follow-up tests, and may even be experienced by people other than the person being screened 
(34;37). As Karnon (37) notes, the introduction of a universal first trimester ultrasound scan 
may lead to a growth in unnecessary anxiety, simply because foetuses with serious defects 
which would otherwise have led to a miscarriage will now be detected, and an active decision 
to terminate the pregnancy may have to be made.  However, the fact that screening permits 
such decisions to be made might, according to Mooney & Lange(38), mean that older women 
who might have thought twice about screening in the absence of screening would now 
consider conceiving, prompting the birth rate to go up. This postulation has not been 
substantiated, nor is it as yet possible to find evidence to support the notion that termination 
rates (out of the total number of pregnancies) would rise as a consequence of introducing an 
additional ultrasound scan (2). 
 
There are no inherent health benefits associated with the screening process itself (39), 
however, irrespective of the outcome, parents’ access to screening facilities may give rise to 
feelings of empowerment and control (37), the main short-term benefit constitutes 
information. In the longer term, the provision of such information may or may not lead to 
health interventions being carried out. In most postnatal screening processes, this means that 
diseases may be treated and lives may be saved. As mentioned, such interventions do indeed 












or immediately after birth,. This would however, only mean that screening has any value if it 
yields certain outcomes. The isolated value of the screening process is rather, according to 
Cairns (40), derived from the information it provides which should form the basis of decisions 
that in some way are different – presumably better - from those that would have been made in 
the absence of this information. Cairns is nevertheless quick to point out that value may not 
necessarily depend on the decisions made on the basis of screening information, but merely 
on the supply of the information itself. In other words, a screening test may be of value even 
if its results do not have any bearing on prognosis or any subsequent intervention (34). 
Berwick and Weinstein (41)for example, found that a quarter of the value gained by pregnant 
women from routine ultrasound screening was not related to any decision, just information for 
its own sake. Lange et al. (42) also found that information from screening – in their case for 
carrier status for autosomal dominant polycystic kidney disease (ADPKD) – was valued even 
among women who expressed  no intention to abort even if they tested positive. 
 
Economic evaluation of antenatal screening 
Whether co-ordinated or not, screening is a health intervention, and as any other health 
intervention it involves benefits and costs. Any intervention involving benefits or costs may 
be subjected to economic evaluation, and screening argues Donaldson (43), is no exception, 
In the case of antenatal screening, one might expect such a position to be - at least mildly – 
controversial. After all, as revealed in Reynolds'  (44) study on British research ethics 
committees’ attitude towards screening, the debate regarding if and when antenatal screening 
is justifiable has by no means been laid to rest. There seems however, to be little debate as to 
whether the benefits and costs of screening should be made explicit. The discussion among 
health economists tends rather to centre on how it is to be done. Perhaps this is to be expected, 
since people who are against screening are likely to base their argument on ethics, thus 
rendering the economics irrelevant. Those who are in favour of evaluation, will have moved 
on from the question of whether screening can be justified on economic grounds to one of “by 
means of which methods can it be carried out?”. Although there now exist well-defined 
criteria that stipulate when screening may be carried out and how the results are to be 
presented, as for example those laid down by the UK National Screening Committee (19), . 
there are no formal guidelines pertaining to the economic assessment of such activities (34). 
There has been a great deal of discussion among health economists regarding methodological 












outcome and hence what type of economic analysis is most appropriate. The arguments 
relating to these issues are summarised below, and although the main focus is on the 
outcomes - or benefits  - side of the equation, the economic analysis of antenatal screening 
poses challenges related to cost calculation which are also accounted for. 
 
Outcomes: Cost-benefit analyses 
Screening is evidently more complex to evaluate than other health interventions as it has a 
wider range of both positive and negative outcomes. Furthermore, it may involve investments 
in both information and – indirectly – in long term health status (39;43). The multifaceted 
characteristics involved, says Donaldson (43), have bearings with regard to the manner in 
which screening is dealt with in an economic evaluation. Several authors (34;40;43;45) 
consider the results of screening tests as a hierarchy of outcomes. In such a structure, the 
number of cases of a given malformation detected for example, would be considered only an 
intermediate outcome whereas a higher-order or final outcome would be the total value of the 
screening process to either a group targeted for screening or society at large.  The most 
appropriate way to assess such interventions, according to these authors, would be to conduct 
a cost-benefit analysis, as this type of analysis is better than a cost-effectiveness analysis at 
capturing final outcomes – or in Donaldson’s (43) words “the ultimate objective”. In cost-
benefit analyses, the objective is to compare discounted future streams of benefits, measured 
in pecuniary terms, and costs in order to measure the net benefits associated with a project 
(46). Hence, the merits of a project or programme can be calculated in absolute as well as in 
relative terms (46): Is it worthwhile to screen at all, and if so, which method of screening 
should be chosen? 
 
However, how does one measure the benefits of screening in money terms? The willingness-
to-pay - or contingent valuation – method, involves asking people how much they would be 
willing to pay for a proposed health intervention (43;47). In principle, the method should 
reflect the total value placed by an individual on the benefits perceived to accrue from the 
intervention.  A few studies of this sort have been published in the field of antenatal 
screening. For example, one by Berwick and Weinstein (41) which revealed that 44 % of the 
value attributed to screening by women with normal pregnancies was related to information 
which had no medical significance. Another, by Caughey et al. (48) from California, showed 












also used with regard to cystic fibrosis screening (49) where women were asked to state their 
willingness-to-pay before and after the test. The results indicated that those women who 
tested negative were willing to pay 16% more for the result than their stated pre-test 
willingness to pay. Theoretically tempting as the method may be, it involves a number of 
caveats, apart from the issue of the timing of the question. Donaldson (49) has argued that the 
further away one moves from a concrete measure such as the number of detected cases 
towards some general measure of wellbeing , the harder it gets to measure. Moreover, the 
researcher has to decide whom to ask (likely candidates for the intervention or a sample of the 
general population). Some people may consider the concept rather alien, either because they 
are not used to being charged for health services (4), as would be the case in Norway, or 
because they are reluctant to place monetary values on life and suffering  (34).  
 
Outcomes: Costs averted  
Not everyone is averse to placing a monetary value on life and suffering, indeed that is what 
health economists do. So-called cost of illness studies abound in the health economic 
literature  These studies assess the direct and indirect costs that arise due to a disease or 
condition, whether it be predominantly congenital such as multiple sclerosis (50), or lifestyle-
related such as obesity (51).  The purpose of studies like these is to demonstrate the economic 
benefit of reducing or  removing the disease (52). Therefore, they are likely to be useful in 
planning health care spending (53) and making priorities regarding research (52). The latter 
may be the reason why organisations for handicapped people sponsor cost-of-illness studies, 
although one could imagine that some of their members could feel stigmatised upon being 
told that their cost of illness, or economic burden of disease, is quite substantial.    
 
One should hence not be surprised upon learning that health economists also place a value 
upon the illnesses and conditions sometimes referred to as anomalies, birth defects or 
malformations, which are investigated during antenatal screening. The objective is rather 
different in the context of antenatal screening however, as the discovery of an anomaly may 
well lead to its removal, and disregarding foetal medicine for a moment, this is impossible 
without also removing the potential life to which it is attached. 
 
The notion of placing a value on a life – or rather the removal of such – becomes particularly 












averted”, as a result of discovering and then aborting an affected foetus are included. These 
savings are often treated as benefits in cost-benefit analyses, although they should strictly 
speaking, according to Shackley (47), be treated as costs. Indeed they often are in cost-
effectiveness analyses, as discussed later. The earliest economic evaluation of screening for 
Downs syndrome, a cost-benefit study by Gill and colleagues from 1987 (54), was according 
to Karnon (37) of the “costs averted” type. In this study, the difference between the lifetime 
costs of taking care of a child with Downs and a “normal” child are calculated, multiplied by 
the number of detected cases and incorporated as a benefit. Another study, by Cusick (55) 
employs the same technique, although the net cost of a Downs child seems somewhat 
arbitrarily set at 500 000 US dollars.  
 
The majority of “costs averted” studies are concerned with Downs, although studies 
incorporating the lifetime costs of spina bifida (56;57) as well as other anomalies such as 
major cardiac disease, cleft lip or palate, renal agenesis or dysgenesis, urinary obstruction, 
lower or upper limb reduction, omphalocele, gastroschisis, and diaphragmatic hernia have 
been published (57). In addition, Karnon et al. have calculated lifetime treatment costs of 
beta-thalassemia  (58) and sickle cell disorders (59) and suggested that they be used in 
screening evaluations. Brown and Buxton (34) note that some authors may have qualms about 
such studies and therefore do not incorporate any benefit measurement beyond the number of 
cases detected. They maintain however, that the omission of what they call the “true effect”, 
i.e. the costs averted, involves a failure in addressing the full resource implications of 
initiating a screening programme.  It should be pointed out that they also emphasise the costs 
that may be saved as a result of improving the prognosis of a foetus which is not removed. 
One could argue that the costs averted approach should not be seen as being any more 
incorrect from an economic standpoint than one involving a cost of illness. One could further 
argue that an anticipation of the economic burden associated with extra care is a real factor in 
determining people’s decisions to screen, especially in countries with a low level of public 
health care provision. 
  
Other authors are less positive, and have criticised the studies of the “cost averted” type  for 
the implied assumption that there are no net benefits from a true positive result (38;43;60) and 
for not considering the fact that parents might not choose to terminate.  The value of the un-
terminated life is not calculated but for the economic burden it imposes on society (61).   












the studies, in Macones’ view (60), account for “collateral damage” – the loss of a foetus as a 
result of CVS or amniocentesis, which – if a consistent logic were to be followed  – would 
incur a lifetime’s productivity loss. The inclusion of the costs and benefits that are to be added 
tends to be a normative affair, argues Cairns et al. (40) referring to the practice of adding the 
costs of lost output for a life with Downs syndrome, adding drily that:  “For most parents, 
children yield benefits exclusive of their contribution to output.” (Cairns et al., 1992, p. 109) 
As Alderson puts it, these studies miss out on the huge variation in severity and functional 
capacity of children with Down syndrome, and what kind of life children with Down 
syndrome get to lead.   However, the essential point made by Cairns et al. is that there are no 
objective outcomes in the area of antenatal screening. Or as Donaldson (43) puts it, the benefit 
measure depends on the question the analyst is seeking to answer. 
 
Cost-utility analyses 
Might then cost-utility analysis be a more appropriate tool with regard to the evaluation of 
antenatal screening? This type of analysis involves an outcome measure which takes into 
account of the quality of health states experienced over time, expressed for example in the 
quality-adjusted life year (QALY) in which health states are assigned a utility weight from.0 
(dead) to 1 (perfect health) (46). While retaining the feature of a generic outcome unit that 
facilitates comparison across different types of interventions (34), it avoids the potential 
controversies associated with valuing the results in pecuniary terms. Despite this, there are 
very few cost-utility studies of antenatal screening. One study of this variety was published in 
Norway in 2007; Killie et al. (62) measured the number of quality-adjusted life years accruing 
to pregnant women screened for neonatal alloimmune thrombocytopenia. The quality of life 
measures however, appear to relate to the children that may be treated for this particular 
disease after birth, and not to the utility or disutility generated by the antenatal screening 
programme to the parents prior to birth. Harris (63) too looks at isolated parts of the screening 
process in his 2004 cost-utility study of  screening for Down syndrome with and without 
invasive testing (amniocentesis and CVS), but the design of the study was seemingly aimed at 
isolating the effects of diagnostic testing. This segmentation is perhaps due to the potential for 
changed utilities over time.  On the one hand it appears to be difficult to design a study that 
measures utilities in relation to an exhaustive screening programme given that one would 
either have to question women over several points in time or ex post. On the other hand some 












capture the disutility related to transient screening-related anxiety which will hence not appear 
in the cost-utility estimations. Petrou (64) notes that preferences for certain health states may 
differ depending on whether or not the pregnant woman has experienced them and points out 
that parents may adjust well to bringing up a child with Down syndrome. Mooney and Lange 
(38) are also concerned with preferences and information, but this time with respect to the 
doctor-patient agency relationship and thus whose preferences enter the equation; the 
obstetrician’s, the midwife’s or the pregnant woman’s. There may be a host of reasons for the 
small number of cost-utility studies in this area. Eliciting utilities is a time-consuming 
process. Moreover, even though money is no longer the outcome, one hasn’t entirely left the 
ethical minefield since some maintain that it is not only the preferences of pregnant women 
that may be measured, but also for example those of the public at large or people with Down 
syndrome or some other condition for which there is a screening test .  
 
Cost-effectiveness analyses 
Cost-effectiveness studies measure outcomes in terms of natural units such as life years 
gained or strokes avoided and are particularly suited for cases where a specific outcome is to 
be maximized under a given budget (46), assuming that at least one of the alternatives is 
worthwhile.  The focus is hence on relative efficiency, and the main advantage of the method 
is its simplicity: This type of evaluation however, only permits one type of natural unit to be 
compared at a time. Cost-effectiveness analyses therefore miss out on the broader benefits of 
ultrasound. Since the outcome selected most often is related to the search for and discovery of 
an anomaly, the outcome does not capture other benefits of screening including the value of 
reassurance, information and so on. These items are in a sense intangible, and may be left out 
precisely because they are so difficult to integrate consistently in an analysis. That is not to 
say that all cost-effectiveness studies of antenatal screening relate to anomalies for which 
nothing can be done: For example, a study from Finland from 1996 (65) based on a 
randomised clinical trial of 9 310 women compared the effect of one-stage ultrasound to no 
ultrasound on perinatal mortality and found a cost per perinatal death avoided of USD 21 938 
(1996-prices).  
 
As mentioned previously, the analysis should be geared to the question one wishes to answer. 
Therefore, in moving from the domain of allocative efficiency (cost benefit or cost utility 












how often, cost-effectiveness analysis may be the most appropriate method (34;47). It is 
however, important that the evaluation should capture the essence of the programme 
investigated. The number or proportion of cases detected with a given condition has been used 
as an outcome measure in economic evaluations of antenatal screening (34), in which results 
are expressed as costs per (additional) case detected. For some, such a measure is arbitrary 
and doesn’t carry any inherent value. Sassi (45), for example, believes the measure is a 
“shortcut”. However, repackaging, as it were, the measure in the phrase “reproductive choice 
over the outcome of an affected pregnancy” seems more constructive and easier to grasp 
(34;66). Though “affected pregnancy” might mask a wide variety of conditions, since an 
ultrasound scan can indicate the presence of more than one disease, it makes decision-making 
more complex (39). Would it be fair for instance, to lump anomalies of different degrees of 
seriousness together into one generic “detected case” measure? One solution to this challenge 
is to categorise conditions into a few broad groups, as was done by Bricker et al. in the UK 
(67). This leaves the question of how much the discovery of an additional “affected 
pregnancy” is worth, or in other words; what constitutes a reasonable threshold within which 
the incremental cost effectiveness ratio has to lie (34)? 
 
Some cost-effectiveness studies go further than measuring cost per detected case. Ritchie 
(68), for example, includes the cost of terminating an affected pregnancy, and is in this regard 
not quite aligned with the “reproductive choice” notion. Odibo et al. {Odibo, 2005 10 /id, 
although they stop short of calculating extra costs to the life of a child with Downs syndrome, 
do record the number of live born babies with the condition as an outcome as well as the 
number of detected cases. This assumes some decision as to whether or not to terminate has 
been taken regarding the foetuses with positive tests.  Harris (69)  too adopts the same 
procedure. Other studies, such as Cusick et al. {Cusick, 2003 477 /id}, and Vanara et al. 2004 
(70)go further, and may be seen as being in the same vein as the “cost averted” studies 
discussed earlier. However, as opposed to the “cost averted” studies, these evaluations handle 




As we have seen, much of the debate on economic evaluation of antenatal screening tends to 












upon some cost issues with regard to what items to include, or in other words, when to stop 
including them. However, there are further costs issues, perhaps more technical in nature 
compared to those associated with the benefits, but which may nevertheless lead to significant 
variation in results, and which therefore render interpretation and comparison of results in this 
field difficult.  Problems associated with the cost side of the fraction might be how to address 
shared resources, for instance among different diagnostic procedures and tariffs which do not 
necessarily reflect the opportunity cost of scanning or diagnostic services (45). An expansion 
of a screening programme  may, rather than a replication of entire facilities, involve 
reorganisation and efficiency gains which are not reflected in costs if they are measured by 
proxies such as tariffs.  Brown & Buxton (34) cite an example of a small increase in screening 
which will involve incremental costs lower than current average costs, since the latter already 
embody costs of investments in specialist equipment. Because of differences in capacity and 
potential economies of scale, screening costs may well differ significantly across contexts.  
 
Realistic costing studies which document actual resource use are therefore warranted. An 
example of a rather thorough costing study which attempted to measure the ”real” costs of 
ultrasound scans was Henderson et al., which utilised top-down and bottom-up methods to 
elicit the cost to the NHS, pregnant women and their employers of ultrasound scans at 
Liverpool Women’s Hospital in 1998 and 1999. The study concluded that routine scans cost 
in the area of GBP 14-16 per scan. Follow-up procedures were significantly more expensive. 
The opportunity cost of time to the women and their employers were estimated to lie in the 
region between GBP 9 and 15. Costs proved to be lower than what was found in the literature 
at the time, and were also used as input data in the evaluation by Bricker et al. (67). Bricker et 
al. stressed that indirect costs are important, but it could be argued that their method of 
measurement was somehow inequitable: The time of women going for a scan while at work 
was measured using the hourly wage rate GBP 5-37 net of taxes and social security 
contributions. Meanwhile, the time of employed women who were on holiday while the 
examination was carried out was valued at 40 % of the working women’s time, GBP 2.15. 
The authors acknowledge that the valuation of leisure time was to some degree arbitrary, but 
state that the measure was used in a sensitivity analysis. What seems rather peculiar, however, 
is that they value the time of unemployed women – who are assigned an opportunity cost of 
time corresponding to that of cleaning work or informal care, GBP 4.  An unemployed woman 
going for an ultrasound scan thus brings about a higher cost to society than an employed 













As with other types of technology, the more advanced the machine, the more expensive it is 
likely to be, a feature which was duly noted by Hagenfeldt et al., who in their 1998 evaluation 
of routine antenatal ultrasound screening in Sweden  divided the scanners  into three 
technology classes. A simple scanning technology class with 2-dimensional and simple 3-
dimenstional machines  with a purchase price of up to SEK 400 000, a medium class with 
colour flow and spectral doppler which could be used to measure fluids (up to SEK 800 000) 
and a top class, incorporating technology of similar features as the medium class, but more 
advanced in terms of diagnostic precision, at a cost of up to SEK 1 200 000. The machines in 
the top tier were thus 3 times more expensive than those in the bottom. The rapid 
technological advances seen in ultrasound technology pose many challenges. Not only do the 
costs of the machines vary, but another implication is that results of studies using different 
technologies are not readily comparable. The technology itself however, is only half the story. 
As Tegnander (71) points out, the skill of the operator with regard to the interpretation of a 
fuzzy screen image also plays a significant role in determining test performance.  
 
It is therefore not surprising that reviews of costing studies and economic evaluations of 
ultrasound screening show a large variation in the cost per scan (67;72;73). Roberts et al., for 
example, found the cost of a routine scan to range from GBP 18 to GBP 204.  Given the 
circumstances, it would have been helpful to have had access to Norwegian economic 
evaluations with which to compare our results. Unfortunately, we were not able to find any 
recent economic evaluations, nor any costing studies from Norway. The closest we came was 
a study by Backe and Buhaug from 1994 (74) and one even older by Bakketeig and 
colleagues (75). The study estimated the societal costs of antenatal and obstetric care for 1908 
women in a Norwegian county over 12 months. However, the data were from 1988-89, 
meaning that they are now 20 years old.  Moreover, the cost of ultrasound was lumped 
together with that of outpatient visits, and together these accounted for 4% of the estimated 
mean cost per woman of NOK 36 300.  The cost of antenatal screening was hence not very 
large in comparison with the total costs of pregnancy and childbirth. The largest components 
were those of delivery in hospital (36%) and indirect costs related to work absence (43%). 
The study by Bakketeig et al. was based on a randomised trial comparing ultrasound in either 
the 19th or 32nd week of gestation to routine antenatal care at a time when a second trimester 
scan was not common practice. They found an average extra cost per pregnancy of USD 250 












probably provided relevant costing information at the time of publication, but due to the rapid 
change in the design and use of ultrasound technology, there is clearly a need for more 
updated costing studies in Norway. To be useful in an economic evaluation covering Norway 
as a whole, such studies should encompass costs from several facilities, taking into account 
the differences in facility size and utilisation rate.  
Expansion of screening programme 
Evaluation of an expansion of screening to include the combined results of first and second 
semester ultrasound scans is slightly more complex than measuring the effects of an 
intervention in separate trimesters and compare them to each other. This is because a 
combined detection rate has to be calculated, sometimes for several anomalies. As Gardner 
(76) points out, the assessment of a second trimester test should not be treated as if the first 
trimester never happened. In other words, the tests constitute an additional intervention, rather 
than a substitute (45). There is also the possibility that the first trimester intervention may not 
be an ultrasound scan, but a serum test. Odibo et al. (77) for example, compared altogether 
nine strategies, none of which incorporated a routine ultrasound scan in both trimesters, but 
concentrated on a combination of serum tests and ultrasound screening. On the whole, there 
seems to be few economic studies available in which the expansion of a screening programme 
to include a first trimester scan is evaluated, though we have found two studies from the UK: 
Bricker et al. (67) and Ritchie et al. (68). Bricker et al. compared eight options involving 
scans in all three trimesters in a decision-analytic model for England and Wales. However, 
they point out that the objectives of the first and third trimester scans are not primarily to 
discover anomalies. In the former, the so-called “booking scan” performed at 12-14 weeks, 
the aim is to determine gestational age, foetal viability, and whether there are multiple 
pregnancies. Some types of malformations may nevertheless be discovered. The latter scan 
aims to discover the position of the placenta, if there are any foetal growth restrictions, or to 
investigate umbilical arterial flow, but here too anomalies may be detected as a “by-product”. 
Bricker et al. calculated combined sensitivities for the scans in the different strategies to 
determine the detection rate for two specific anomalies (Downs syndrome and spina bifida) 
and two groups of anomalies (congenital heart defects and lethal anomalies). They found that 
the test performance varied for different types of anomaly across trimesters. The second 
trimester anomaly scan alone was deemed to be the most appropriate reference case given that 
it was cheap but still detected a large number of anomaly cases. The first trimester scan 












Royal College of Obstetricians and Gynaecologists (68)along with a second trimester 
anomaly scan. In the Ritchie et al. study (68) a couple of years later covering Scotland, a first 
trimester nuchal translucency (NT) scan was included in the six strategies compared, whilst 
the third trimester scans were ignored. Serum tests in both trimesters were also analysed. The 
detection rates for eight types of anomaly were examined1. The most cost-effective option 
was a combination of first and second trimester scanning and first trimester serum screening 
for chromosomal anomalies. The difference in conclusions between the two studies from 
neighbouring regions only a couple of years apart demonstrate the significance of the rapid 
development in antenatal ultrasound technology. 
   
Conclusion 
Antenatal screening has a lot in common with regular screening, but there are also clearly 
some differences: Antenatal screening is more multidimensional in terms of both how the 
tests are carried out and what they might reveal (39). The consequences of antenatal screening 
may in some cases also appear more dramatic than most other screening processes, even 
screening for potentially lethal diseases such as cancer or AIDS. It is therefore reasonable to 
expect that the economic evaluation of antenatal screening is somewhat more complex than 
the evaluation of other screening processes. Although, to cite Nilsson et al. (73), the 
availability of economic evaluations of antenatal screening may be relatively good this does 
not necessarily imply that the evidence base supporting a particular policy is wide. 
Transferring results from one context to another may be challenging and even inappropriate.  
The incidence and prevalence of the screened condition(s) may be different across 
geographical areas (34), as may be the relative prices and organisation of care (73). The type 
of technology and skills of the operators is also likely to vary, and is inextricably linked to the 
time at which the study was carried out.  Hence, the gestational age at which the scans are 
performed is only one factor that may serve to explain the variation in costs and effectiveness 
in screening programme evaluations. The capacity level, technological standard, operator 
skills and costing methods are others, which mean that the comparison of studies across 
geographical contexts and time should be undertaken with caution. 
 
                                                 














As screening interventions became widely employed, there has also been a development of 
standardised guidelines as to when a screening procedure is appropriate, and how the 
performance of the screening tests is to be evaluated. One example is the guidelines 
formulated and updated by the National Screening Committee in the UK (19). No such 
consensus has hitherto been established for the conduct of economic evaluation of screening 
programmes, however. Petrou (78;79) and Sassi (45) argue that many evaluations of antenatal 
screening are of poor methodological quality, particularly with respect to capturing the full 
range of costs and benefits. However, such an objective may be considered somewhat 
ambitious as long as there is no established consensus as to what, precisely, the full range of 















Type of analysis 
The objective of this study is to assess the costs and consequences of an extension of the 
Current ultrasound screening programme to incorporate universal testing in the first trimester, 
with or without the use of serum hormone tests. As noted in the preceding chapter (literature 
review), the choice of outcome measures in a study such as this is not obvious. However, 
since one may have qualms about the pricing of a life avoided method, a cost-benefit analysis 
is considered unfavourable in this context.  There do not seem to be any Norwegian quality of 
life surveys available that could be used in a cost-utility analysis. Following the example of 
Bricker et al (67), it seems reasonable to restrict the analysis to a cost-effectiveness analysis, 
estimating the number of detected cases of both Down syndrome (DS) and serious congenital 
heart defects (SCHD). Costs are recorded up to the point at which a potential follow-up 
diagnosis either confirms or rejects the presence of an antenatal anomaly. Whatever happens 
thereafter is beyond the scope of this analysis. The results will be expressed as the 
incremental cost per extra anomaly detected, which is the incremental cost effectiveness ratio 
(ICER) of a programme extension relative to Current practice. The costing is carried out from 
the perspective of a third-party payer. Indirect costs are accounted for in the form of lost 
productivity, but travelling costs are not included. 
 
A simple decision-tree model has been developed using TreeAge™ (80), in which three 
strategies are compared (see below), on the basis of published effectiveness data from 
Scandinavian and Norwegian prevalence and cost sources. The model follows a cohort of 
60 000 women (i.e the approximate number falling pregnant in Norway annually) through 
their first and second trimester of pregnancy. The strategies compared are referred to as 
Current, Comprehensive and Combined, as detailed in the Introduction chapter.  
Effectiveness data 
Effectiveness data have been derived from a review of systematic reviews of antenatal 
ultrasound screening conducted by Reinar et al (15). The review suggested that it is difficult 
to compare results across studies characterised by different criteria with regard to defining the 
high risk group, differing mean population age and often small population size. Furthermore, 












technicians and midwives improves. The most recent review covered in Reinar et al was 
Nilsson et al (73), a report from the Swedish Agency for Health Technology Assessment 
(SBU). The randomised trials and observational studies employed as effectiveness data here 
are primarily drawn from Nilsson et al. However, only a few of the studies summarised in that 
study provide useful input data for the purposes of the analysis. An attempt has been made to 
select studies based on the following criteria: 
 
• The population should to the greatest extent possible match the Norwegian pregnancy 
age-distribution, so as to reflect its risk profile. 
• The study should be as up to date as possible in order to incorporate the contemporary 
standard of technology and skills of the operators. The cut-off year was 1998, as 
defined by Nilsson et al. (73), from which the studies are drawn. 
 
There are some challenges in employing effectiveness studies that focus on one anomaly at 
one point in time. First of all, in practice, ultrasound screening involves a process of 
examination that can identify more than one anomaly. The costs of the scan are hence shared 
and independent of how many cases of each anomaly is detected.  The cost of follow-up 
diagnostics however is not, and is determined by a two-stage process: First, the likelihood of 
testing positive for one or the other of the anomalies is determined by combining sensitivity, 
specificity and prevalence data from the studies. Second, the individual share of positive tests 
of each anomaly is calculated out of the total testing positive. This enables the results to be 
expressed as a single measure of effectiveness (the sum of detected cases of each anomaly)) 
and cost and also to be broken down by anomaly. The study data however, are drawn from 
populations that are not necessarily identical in terms of age and risk distribution. The second 
challenge relates to the fact that the effectiveness data from the second trimester is 
independent from that of the first. Rather than measure the effect of two scans on one 
population, the second trimester data results are from an unselected population with no prior 
risk stratification. This has been handled by reducing the prevalence rates of the two 
anomalies in the second trimester part of the model by removing the detected cases and 
confirmed negatives in the first trimester from the model population destined to be scanned in 
the second trimester.  If this were not done, it would have been the same as assuming that 
there had been no tests at all prior to the second trimester, and one could have risked that the 














Nilsson et al (73) found 22 studies from the period 1998-2005. In terms of population, one of 
the studies was high risk, one low-risk, seven not given and the remaining 13 were unselected. 
The study by Prefumo et al. (81) from the UK on a selected high-risk population of 510 
women scanned in the first trimester with NT was used for the sensitivity and specificity 
variables in the high-risk group in the Current strategy, but the standard Norwegian Down 
syndrome prevalence rate of 2.0 per 1000 was retained. This seems like a useful method, 
given that Greenhalgh (21)  has pointed out that sensitivity and specificity are not affected by 
prevalence, but the positive predictive value , i.e. the probability of having a condition after 
having tested positive for it. The data for the first trimester in the Comprehensive strategy and 
the second trimester in all strategies were taken from Saltvedt  from  2005 (82), a Swedish 
randomised controlled trial in which a total of 39 572 pregnant women were either scanned at 
12-14 weeks of gestation, including NT screening, or at 15-20 weeks, with screening based on 
maternal age. First trimester data for the Combined strategy were drawn from Wald et al. 
from 2003  (83), also known as the SURUSS study. This was a prospective study which took 
place at 25 centres – one in Austria, the rest in the UK, at which 47 053 pregnant women were 
screened with ultrasound plut NT and serum tested in the first trimester.  
 
Table 1 Effectiveness data: Down syndrome 
Trimester Strategy Study Sensitivity Specificity 
1st trimester Current (high risk) Prefumo et al. 2006 0.87 0.503 
 Comprehensive and  
Current (low risk) 
Saltvedt  et al. 2006 0.76 0.962 
 Combined Wajd et al. 2003 0.85 0.939 
2nd trimester All Saltvedt  et al. 2006 0.61 0.817 
 
Serious congenital heart defects 
Nilsson et al (73) indentified 15 effectiveness studies of SCHD, of which 9 had an unselected 
population, 2 low risk and the remainder unclear.  As in the case of Down syndrome, there 
were no specific high-risk studies available in the case of SCHD, therefore the same method 
of using the standard prevalence in the high-risk group in the Current strategy was applied. 
Data from Westin  (84), a study from Sweden from 2006, was chosen as the source of first 
trimester data for all three strategies. The randomised controlled trial featured 39 572 












SCHD at either 12 and 18 weeks of gestation. The first trimester sensitivity was relatively low 
at 10%, which could be due to the difficulty of detecting malformations in the relatively small 
foetal heart at 12 weeks. The second trimester data were taken fram a Norwegian study by 
Tegnander from 2006 (1), in which 42 381 foetuses where investigated for serious congenital 
heart defects in the second trimester. The specificity in this study was 1, meaning that all 
negative cases were confirmed as such.  
 
Table 2 Effectiveness data: Serious congenital heart defects 
Trimester Strategy Study Sensitivity Specificity
1st trimester All Westin 2006 0.1 0.992
2nd trimester All Tegnander 2006 0.41 1
 
Probablities 
The data summarised in Nilsson et al (73) include sensitivity and specificity, from which one 
may calculate some of the other probabilities required in the decision model:  the risk of 
testing positive and the subsequent risk of being confirmed positive, which are used to 
calculate the number of detected cases.  
 
The positive test rate ptr denotes the chance of testing positive in either trimester, whether it 
be for Down syndrome or serious congenital heart defects, and may be calculated on the basis 






















Since the model requires the calculation of the share of patients testing positive for either 
Downs or SCHD, the ptr has to be calculated on a group level, in which the parameters of the 
individual studies are combined. 
 
SCHDDSG ptrptrptr +=  
 
The risk of being confirmed positive  will depend on how many of those who test positive 
choose to receive follow-up diagnostics (discussed below) and of these, how many will 
actually turn out to have the condition, which is the positive predictive value,  ppv. 
 






ppv =  
 
As opposed to the ptr, the ppv at the group level is not the sum of the ptr of the subgroups, but 
can be expressed as a fraction with the sum of the detection rates of both anomalies in the 
numerator and the sum of the positive test rates in the denominator. The detection rate denotes 
the reate of detected true positive cases to the number of cases tested. 
  
Detection rate, Down syndrome  
 
DSDSDS ptrppvdr ×=  
 


























Unfortunately, it has not been possible to find any costing study of the type conducted in 
Liverpool in 2001 (85) which could provide an idea of the real cost of performing an 
ultrasound scan or a antenatal diagnostic procedure. Even if one were available, hospitals 
which offer ultrasound scans in Norway tend to vary significantly in size and in regard to the 
population density of the area they serve. Moreover, ultrasound scans are also offered by 
general practitioners (GPs). There would thus be some uncertainty as to whether the costing 
figures would be representative on a national level. Therefore, tariffs – or rather 
reimbursement claims for different procedures from GPs and hospital outpatient departments 
to the National Insurance Administration, have been chosen to represent costs. Even though 
such charges are, as pointed out by Sassi (45), unlikely to reflect the opportunity costs of the 
procedures they represent, it may be argued that they at least represent the potential change in 
government expenditure in the short run. This argument is referred to in the methodological 
costing review conducted by Mogyorosy and Smith (86). It is not an ideal method, but for the 
purposes of the present study, it constitutes the only feasible solution. It is apparent however, 
that the tariffs do not represent opportunity costs in that they are clustered in groups. For 
example, the tariff for abdominal and transvaginal ultrasound and antenatal counselling are all 
the same. The charges or reimbursement rates associated with the procedures relevant to the 
model and applicable in 2006 are shown in the table below.  
 
Table 3 Reimbursement rates antenatal screening and diagnostics 
Procedure Tariff code Tariff, 
Norwegian 
kroner 2006 
Abdominal or transvaginal ultrasound scan B20c/B20i 219 
Consultation charge B02 127 
Antenatal counselling B20h 219 
HCG/PAPP-A blood test  701h (GP) 31 
Amniocentesis/CVS B21f 389 













Indirect costs are calculated on the basis of the expected productivity loss associated with the 
different procedures (including travel time) and the average hourly wage rate for women in 
2006 (87). The ultrasound scans are assumed to take half an hour, while follow-up diagnostics 
and counselling sessions are assumed to take a full hour  (88). An hour is also added for 
travelling purposes, though the costs of travel itself is not included due to lack of reliable data. 
All women are assumed to work, and to return to work immediately after the consultation. 
Model structure 
 
Except for the Current strategy, in which the first node represents the chance of being scanned 
in the first trimester, the first node in all strategy branches determines the risk of a pregnant 
woman testing positive for either DS or SCHD.  By structuring the decision tree in this 
fashion, it is possible to separate the costs for ultrasound screening and those that arise due to 
follow-up diagnostics. The cost of the former will be incurred whether or not a case of 
antenatal anomaly is actually detected. Those testing negative will proceed to the second 
trimester scan.  
 
For those who test positive, the subsequent node denotes the probability of the woman 
proceeding to diagnostic follow-up. As pointed out in Chapter 1, such procedures are in the 
case of DS not risk free, and many may therefore opt not to go through with them.  However, 
the actual proportion is not known. It may tend to vary according to age, type of test and at 
what time it is carried out (73;89). Intuitively, one might expect the rate to be higher in the 
first trimester, as the opportunity to terminate the pregnancy if any anomaly is found might be 
perceived as greater than would be in the second. Invasive tests, which are relevant for Down 
syndrome, are most likely more of a barrier than a non-invasive further ultrasound scan, 
which would be the option for serious congenital heart defects. A standard propensity to 
pursue follow-up diagnostic testing across both anomalies and trimesters has been assumed 
and this figure has been varied in the sensitivity analysis from 50 to 100%.   
 
Those who test positive and who choose to proceed to follow-up diagnostics are either 
confirmed positive and added to the number of detected cases or confirmed negative. In either 
case, they are subtracted from the remaining model population so as to avoid being counted as 













Those who test negative on the first trimester scan will proceed to be scanned in the second 
trimester. As the effectiveness data for all strategies are the same for the second trimester, the 
only variables that will differ among the strategies here are the number of pregnant women 
who will be scanned in each case, as those confirmed positive have been removed from the 
model population and the prevalence rate at this stage. The second trimester branch structure 
is more or less identical to that described for the first trimester. At the triangular terminal 
nodes, the accumulated number of detected cases is counted for each strategy, as are the costs.  
A graphic representation of the decision tree is shown in the appendix. All strategies have 
















This chapter presents the results of the cost-effectiveness analysis performed using the 
decision analytic model which follows a cohort of 60 000 pregnant women through screening 
and diagnostic procedures during the first and second trimesters of pregnancy. The model’s 
primary outcome measure is the total number of detected cases of Down syndrome and 
serious congenital heart defects associated with each strategy. A detected case is a result of a 
positive ultrasound scan and subsequent confirmation through diagnostic testing. In addition, 
the number of false positive cases generated by each strategy is calculated. False positive 
cases are defined as those who test positive in either of the two trimesters covered, but who 
are classified as negative at the completion of follow-up diagnostics in the second trimester. 
Direct costs, which are the costs borne by the publicly financed health care sector as well as 
by the patient in the form of co-payment, are presented along with total costs, which are the 
sum of direct costs plus indirect costs. These are presented separately and per detected case in 
the base case analysis. All costs are measured in Norwegian kroner (NOK) or in million 
Norwegian kroner (MNOK) in 2006 prices.  
 
The presentation of the base case analysis includes a scrutiny of the composition of the 
outcomes and costs. Finally, the effect of changing the assumptions with respect to the 
probability that positive testing women will undergo follow-up diagnostics and the 
relationship between costs and tariffs is explored in the sensitivity analysis.  
Base case analysis 
Number of cases detected 
Table 4 below shows the total number of cases detected in each strategy. In the Current 
strategy, a total of 468 cases of Down syndrome and serious congenital heart defects are 
found. The Combined strategy, which incorporates a first trimester serum test as well as 
ultrasound, generates the highest number of detected malformations of 625. The strategy is 
however, only marginally – five cases – better in terms of the objective of detecting the most 
cases relative to the Comprehensive strategy. The latter is identical to the Combined strategy 
but for the serum test. Compared to the Current strategy, which involves the public provision 












incorporating first trimester universal ultrasound scanning enable the number of total cases 
detected to increase by approximately 33%.  
 
Table 4 Number of detected cases by strategy 
Strategy Number of detected cases Incremental number of detected cases 
Current 468  
Comprehensive 620 152 
Combined 625 157 
 
The results shown above are based on the assumption of 67% diagnostic follow-up based on 
the experience from the Centre for Medical Geneticsl in Bergen (90), i.e. that two thirds of the 
women receiving a positive ultrasound scan will, after attending a counselling session with an 
obstetrician, proceed to diagnostic testing. As mentioned previously, the model only follows 
the cohort of pregnant women to the diagnostics stage in the second trimester, and not to the 
pregnancy’s final outcome, whether it be delivery or abortion. Since the follow-up rate is set 
at a figure less than 100%, some women who test positive but who are not confirmed as such 
will neither be classified as a detected case nor as a false positive case. The rate is highly 
uncertain and has therefore been varied in the sensitivity analysis, but since the model only 
permits a uniform rate, this does not capture the potential differences in the uptake of follow-
up testing between the two anomalies. These can be expected to differ in that the confirmation 
of Down syndrome involves invasive tests whereas the detection of serious congenital heart 
defects does not (1). 
Direct, indirect and total costs 
The annual direct costs associated with the Current strategy are NOK 33.2 million for 60,000 
pregnancies, or NOK 664 per pregnant woman in the model cohort. The two strategies 
incorporating universal first trimester routine ultrasound scanning both incur additional costs 
in the region of NOK 33-36 million, increasing the cost per pregnant woman to almost NOK 
1,400. The incremental cost associated with the Combined strategy however, is higher than 














When the indirect costs are included, the costs in all three strategies are approximately 
doubled. Relative to the Current strategy, the costs in the two universal first trimester 
scanning strategies rise by more than NOK 50 million. Again, there is only a small difference 
between the two first trimester universal scanning strategies at NOK 9.1 million, which 
translates into NOK 150 per pregnant woman. As stated in the Methods chapter, the indirect 
costs are calculated on the basis of the hourly wage rate, assuming all pregnant women are 
employed and not on any form of leave at the time of the scan. This is a relatively strong 
assumption, which may cause the indirect costs to be overestimated. Some women may leave 
work only briefly for an ultrasound appointment and “catch up” once they return. On the other 
hand, some invasive testing procedures or prolonged counselling may require longer periods 
away from work (88). In addition, many women may prefer to bring their partners along for 
the session; these costs not been included in the model. 
 
Table 5 Direct and total costs 
Strategy Direct costs, 
MNOK 




Incremental total costs, 
MNOK 
Current 33.2  68.8  
Comprehensive 66.3 33.1 122.2 53.4 
Combined 69.4 36.2 131.2 62.5 
 
Cost per case detected 
A comparison of the incremental costs and incremental cases detected with reference to the 
Current strategy show that the Comprehensive strategy may be considered to be relatively 
more cost-effective than the Combined strategy, generating an incremental cost-effectiveness 
ratio of NOK 218 000, which is NOK 12 000 lower than the Combined strategy. 
Nevertheless, implementing this strategy instead of staying with the status quo involves a 
doubling of direct costs whereas the number of detected cases only goes up by a third. When 
indirect costs are included, the incremental cost per case detected in both strategies grows to 





























detected case, NOK 
Incremental 
total cost  
per  
detected case, NOK 
Current      
Comprehensive 33.1 53.4 152 217 763 351 316 
Combined 36.2 62.5 157 230 255 397 771 
 
Changing the point of reference from the Current strategy to a hypothetical strategy of “No 
scanning”, i.e. one where no costs are incurred and no cases found, serves to demonstrate that 
the discovery of the additional cases in the first trimester becomes relatively more expensive 
in terms of the cost per case detected. The incremental costs of the strategies relative to no 
scanning are the same as the average costs. Detecting 468 cases in the Current strategy comes 
at a direct cost per case of nearly NOK 71 thousand, whereas the additional 150 or so cases 
detected in the two other strategies entails an average cost of around NOK 107-111 thousand 
per case.  
 
Table 7 Average costs per case detected 







costs per detected case, 
NOK 
Average total 
cost per detected case, 
NOK 
Current 33.2 68.8 468 70 940 146 902 
Comprehensi
ve 
66.3 122.2 620 106 935 197 016 
Combined 69.4 131.2 625 110 960 209 920 
 
Interpretation of these results is not necessarily straightforward, since no decision rule as to 
what is and what is not cost effective can be ascertained in this context. Norway, unlike the 
National Institute for Clinical Excellence in the UK, does not have a semi-official threshold 
value concerning the willingness-to-pay for health benefits (91). Even if it did, this would be 
of little help as such threshold values tend to apply to benefits expressed in terms of quality-












were to minimise the cost per detected case then retaining the Current strategy is clearly the 
best option. Should the goal on the other hand be to maximise the number of cases detected 
regardless of cost, then the Combined strategy is the most sensible choice. When compared to 
the Current strategy, the other two strategies involve the discovery of some 33% extra cases, 
but the costs rise more than proportionately. What is clear is - provided that first trimester 
universal ultrasound scanning is desired - the Comprehensive strategy is relatively more cost-
effective than the Combined alternative. However, if the population has very high willingness 
to pay for finding these anomalies, the Combined alternative could be considered cost-
effective. 
 
Number of cases confirmed as false positive 
The number of confirmed false positive cases derived from the Current strategy is relatively 
high at approximately 7 000, or 12% of the cohort of pregnant women in the model. In either 
of the first trimester universal scanning strategies, the figure increases by about 611 cases. 
This might appear somewhat odd, since one would expect the implementation of an additional 
scan to generate significantly more positive – and therefore necessarily false positive –cases. 
In practice, this is indeed true, but many of the cases in the model testing positive in the first 
trimester routine ultrasound scan will proceed to another scan in the second if they are not 
confirmed as a detected case in first trimester follow-up diagnostics. The model therefore, 
only counts as false positive those cases which – subsequent to the final opportunity for a 
diagnostic test - are classified as such. In other words, a case may be wrongfully found 
positive in the first trimester, but confirmed as either negative or true positive in the second 
and therefore not counted as false positive at the end. Based on the model estimates, the 
implementation of additional routine scanning and diagnostic testing in the first trimester does 
not contribute to a reduction in the number of false positive cases, but at least the figures are 
kept relatively stable. However, as a consequence of the model’s assumption of 67% 
diagnostic follow up in the base case, as well as ignorance of “interim” false positive cases, 
the final number of confirmed false positive cases presented can not be used as an indicator of 
the number of women experiencing unnecessary anxiety. The model is not designed to 















Table 8 Number of false positive cases 
Strategy False positive cases Incremental false positive cases 
Current 6 972  
Comprehensive 7 583 611
Combined 7 584 612
 
Composition of costs and outcomes 
Breakdown of the number of detected cases and confirmed false positive cases 
A breakdown of the number of cases detected by anomaly is given in table 9 below.  
The vast majority of the cases detected of the two anomalies covered in the model are serious 
congenital heart defects. These have an approximate 90% share of the cases detected in all 
three strategies. This is not particularly surprising, since the prevalence of serious congenital 
heart defects is about 20 times that of Down syndrome. The disparity with regard to the 
respective shares in the total number of detected cases could have been even larger if it were 
not for the fact that the sensitivities in the efficacy data relating to Down syndrome is on 
average higher than those relating to serious congenital heart disease. 
 
The number of detected cases of Down syndrome increases by more than 100% in both the 
Comprehensive and Combined strategies relative to the Current strategy, but the 
corresponding figure for serious congenital heart defects is only 26%. The incremental 
number of serious congenital heart defect cases found is however, significantly larger in 
absolute terms. The five extra cases that separate the Combined strategy from the 
Comprehensive strategy are, as expected, all cases of Down syndrome, owing to the inclusion 
of serum tests for that condition in the former strategy.  
 
With a Down syndrome prevalence rate of 0,002, one would expect around 120 cases of the 
condition to exist in a cohort of 60 000 women. The model estimates 82 cases to be detected 
in the Combined strategy and a few cases less in the Comprehensive strategy, which entails 
the detection of around 68% of all possible cases during the course of the first two trimesters, 
assuming a follow-up rate for diagnostic tests of 67%. As far as serious congenital heart 











cohort would generate some 2 400 cases.  The first trimester universal scanning strategies in 
the model detect approximately 23% of these. In other words, provided that two out of three 
women proceed to diagnostic testing, two thirds of the Down syndrome cases and about a 
quarter of the cases of serious congenital heart defects would be discovered in the strategies 
which include universal first trimester scanning. 
 
Table 9 Breakdown of the number of detected cases by strategy 
Strategy Down syndrome Serious congenital heart defects 
 Total Incremental Total Incremental 
Current 38  430  
Comprehensive 77 39 543 113
Combined 82 44 543 113
 
 
As far as the false positives are concerned, most of these will be cases of suspected Down 
syndrome. This is primarily due to the difference in prevalence rates. Furthermore, the false 
positive rate for the second trimester serious congenital heart disease data used in the model is 
zero. As long as the specificity in the efficacy data in the model’s first trimester strategies is 
less than 1 there will, in a strict sense, be temporary false positive cases, but many of these are 
picked up in the second trimester scan. 
 
Table 10 Breakdown of the number of confirmed false positive ultrasound scan cases by strategy 
Strategy Down syndrome Serious congenital heart defects 
 Total Incremental Total Incremental 
Current 6 785  187  
Comprehensive 7 367 582 216 29














Breakdown of costs 
The structure of the costs associated with the individual strategies can be examined more 
closely by running the model with and without specific cost components using dummy 
variables. It is for example, possible to determine the proportion of each strategy that relates 
to the routine ultrasound scan, counselling and follow-up diagnostics, productivity loss as 
well as patient co-payment.  
 
 Splitting the costs between routine scanning and the services which are dependent upon a 
positive result, i.e. counselling and follow-up diagnostics shows that respectively 6,5%, 7,4% 
and 10,1% in the Current, Comprehensive and Combined strategies are related to follow-up 
diagnostics. In absolute terms, the follow-up costs rise by around two million Norwegian 
kroner following a move from the Current to the Comprehensive strategy, and a further two 
million if the Combined strategy were to be adopted, as shown in table 11. This is brought 
about by higher positive test rates in the two first trimester universal scanning strategies. The 
increase in costs due to additional chorionic villus sampling, amniocenteses and follow-up 
cardiac scans is relatively small however, compared to the cost of implementing an additional 
routine ultrasound scan.  
 
 
Table 11 Direct costs of routine ultrasound, counselling and follow-up diagnostics 







Current 31,2 2,0 
Comprehensive 61,7 4,6 
Combined 63,0 6,4 
 
 
Costs: Patient co-payment 
The direct costs presented here are mainly those borne by the health care system, though a 
fraction of the total expenses are billed to patients as co-payments. The patients’ fees 












total patient share of the Current strategy costs are NOK 13.6 million, which will increase by 
around 14-15 million NOK if the Comprehensive or Combined strategy were implemented. 
Travel costs are not included due to a lack of reliable data. Population densities tend to vary 
across health regions in Norway, and the cost per trip will differ depending on the mode of 
transport.  
 








Current 33,2 13,6 41,0 
Comprehensive 66,3 27,8 41,9 
Combined 69,4 28,1 40,5 
 
Sensitivity analyses 
Rate of diagnostic follow-up 
A one-way sensitivity analysis where the probability of diagnostic follow-up is varied 
between 50% and 100% reveals that this variable has a significant impact on the average cost 
per detected case in all three strategies, as seen in the table below. The difference between 
strategies in this regard is also higher the lower the rate of follow-up diagnostics. 
 
Table 13 Sensitivity analysis: Diagnostic follow-up rate varied between 50% and 100% 
Average cost per detected case in NOK thousand by strategy 
Strategy 50% 67% (base case) 75% 100% 
Current 124,2 70,9 57,2 33,1 
Comprehensive 168,4 106,9 89,7 57,0 














If the rate of follow-up were at the maximum, all three strategies would be able to detect more 
than 1 000 cases of congenital anomalies. However, the absolute difference among them in 
terms of cases detected would not be significantly different from that generated by the base 
case rate of 67%. If all positive ultrasound scans were investigated further, about 94% of all 
Down syndrome cases could be found in the two first trimester scanning strategies, and 44% 
of the serious congenital heart defect cases.  
 
 
Table 14 Sensitivity analysis: Diagnostic follow-up rate at 100%,  
number of detected cases 
Strategy Number of 
 detected cases 
Incremental number of detected cases 
Current 1 024  
Comprehensive 1 173 149
Combined 1 178 154
 
 
Relationship between costs and tariffs 
The direct costs in the model are based on tariffs which – as will be discussed in the next 
chapter – do not necessarily reflect the opportunity cost of the activity they are intended to 
finance. Norway has a system of activity-based financing where tariffs are, on an overall 
level, meant to contribute 40% of the costs of running public health care services (92). The 
remainder is covered by direct transfers from the Ministry of Health. Tariffs then, are not 
likely to represent the full costs of health services because their production has already been 
subsidised. That the tariffs related to ultrasound scanning should represent 40% of the full 
cost is not necessarily a realistic assumption, but it may provide a better picture of the real 
costs than the use of tariffs alone. Therefore, due to lack of a proper costing study, we present 
the results in terms of average cost per case detected in the table below, with all tariffs 
multiplied by a factor of 2.5. As shown in the table below, the average costs per detected case 
rise by approximately the same factor. The costs per extra case detected relative to the Current 












million kroner per case associated with the Comprehensive strategy and almost a million 
kroner with the Combined strategy. 
 
Table 15 Average direct costs per case detected – tariffs x 2.5 (full cost approximation) 
Strategy Direct costs, MNOK Detected cases Average direct  
costs per detected case, NOK 
Incremental direct  
costs per detected case, NOK 
Current 80,0 468 170 940  
Comprehensive 165,8 620 267 419 564 474 














5 Discussion  
 
Policy implications 
The results in perspective 
The results indicated that the number of detected cases with both the anomalies covered in the 
model (with an assumed two thirds of patients (67%) proceeding to diagnostic follow-up) was 
468 in the Current strategy. The number increases by 152 or 157 if either the Comprehensive 
or Combined strategy is chosen. The sensitivity analysis showed however, that an increase in 
the rate of diagnostic follow-up beyond 67% could have a far greater impact in terms of 
increasing the number of cases detected than a change in strategy. At the same time, an 
increase in follow-up leads to a reduction in average cost per detected case and the number of 
unconfirmed false positive cases. It would therefore be reasonable for the authorities to 
encourage increased participation in diagnostic follow-up on efficiency grounds, rather than 
to implement a strategy of universal first trimester scanning. This may indeed be a sensible 
approach with regard to serious congenital heart defects where non-invasive tests are 
warranted. The caveat however, is associated with suspected cases of Down syndrome which 
require invasive follow-up testing. Amniocentesis and chorionic villus sampling involve a 
similar risk of so-called iatrogenic loss or miscarriage of 0.5-1% in addition to the background 
risk of 2-3% (93). This means that 1-2 foetuses will be lost for an increase in invasive follow-
up testing of 3% and 10-20 would be lost if the participation rate increased to 100%. This 
aspect of invasive testing should be taken into account when considering the results, but is 
hard to quantify in economic terms. Hopefully, the need for invasive testing will be reduced 
with the introduction of new methods in the future. The main argument for carrying out 
ultrasound in the first trimester is that the detection rate for both Down syndrome and serious 
congenital heart defects are relatively higher than in the second trimester. With regard to the 
detection of these anomalies, it would make sense to move the scan if the government should 
decide to pay for only one ultrasound examination per pregnancy. However, there are other 
reasons as to why the second trimester scan ought to be retained, as it enables the detection of 













The multidimensional aspects of antenatal ultrasound screening might be one of the factors 
which serve to explain why there seems to be scant evidence for the potential economic 
benefits of introducing universal first trimester scanning, although quite a few European 
countries have adopted such a strategy (2). Other factors include the lack of consensus as to 
how economic studies in this field are to be carried out and how their results are to be 
interpreted. As demonstrated by the literature review, there are few studies available that 
might be compared to the present study. The exceptions are Bricker (67) et al. from 
England/Wales and Ritchie et al.,(68) from Scotland; neither of these is however exactly the 
same as the model presented here in terms of scope.  
 
As noted in the Results chapter, there is no consensus as to what constitutes an acceptable 
limit to the cost per case detected, neither nationally nor internationally. There is no formal 
requirement in the formulation of health policy in Norway, if one disregards the stipulation 
that pharmaceutical companies have to submit a pharmacoeconomic analysis with their 
reimbursement applications to the Norwegian Medicines Agency. The Rights of the Patient 
Act (94) from 2001 does however state that the costs of an intervention should be in 
“reasonable” proportion to the anticipated health benefits, although no definition of the term 
“reasonable” has yet been offered. Even if there were such a threshold – for example with 
respect to a cost per quality adjusted life year – it would intuitively seem much harder to 
develop a decision rule with respect to a cost per detected case. Should all anomalies be 
attached equal weight, for example, or should one distinguish between lethal anomalies and 
serious anomalies with long term morbidity as was done in Bricker et al.’s (67) study? One 
could present the results in terms of a potential increase in the probability of detection: The 
model shows that the overall detection rate could increase from 19% to 25% if a first trimester 
universal scanning policy were introduced. However, this does not circumvent the 
requirement of valuation of detection or its consequences, and is far more complex than for 
example, the assessment interventions designed to prevent road accidents or pollution. 
 
Consequences for the health services 
It is reasonable to assume that the most important questions linked to a potential expansion of 
routine antenatal ultrasound screening in Norway, at least from the publicly run health 
services’ point of view, relate to capacity. Would a move to the Comprehensive or Combined 
strategies, possibly involving an annual addition of some 60 000 scans and a large number of 












equipment, allocated to such activities? Would the workload, primarily for the 463 
obstetricians (95) and approximately 1 300 midwives (96) working full time in Norway in 
2006 grow by such an amount that extra staff would have to be taken on? Would new 
scanners have to be purchased and investments in other capital equipment and administrative 
personnel have to be made? The answers to all these questions are probably negative. The 
reason for this is that there do not necessarily have to be any additional scans: The average 
number of scans per birth in Norway has remained at around 2 for the last 10 years prior to 
2006, albeit with regional and individual variations. Backe’s 1997 study (97) reported that 
46% of pregnant women had met for only one ultrasound examination, but that the mean 
number of examinations performed per woman was 2.2. Since these figures only account for 
the scans administered in the public sector, the overall rate is likely to be higher in 2006 given 
the emergence of private providers in the interim period (88). Backe’s figures suggest that the 
distribution of scans among pregnant women is skewed, and that a minority of women seem 
to undertake a high number of scans. There is unfortunately a lack of recent statistics, 
particularly as to the timing of the scans, but most are liable to have taken place in the second 
trimester. Forbes (98) found a similar pattern in New Zealand in 2004, with an average of 2.1 
ultrasound scans per pregnancy, while 14% of pregnant women had none and 15,4% had 
more than 4 scans.  
 
It is thus highly probable that any need for increased capacity with regard to the number of 
ultrasound scans has already been absorbed subject to the assumption that the average number 
of scans does not increase much beyond 2. There is, in the opinion of Eik-Nes (99), 
significant room for reorganisation in obstetric care to ensure that the number of 
“unnecessary” scans is minimised. There is, for example, little point in undergoing more than 
one scan in the same trimester if no anomaly is suspected. If this does not happen however, 
the number of scans would increase, but it is not possible at this point to determine whether 
investments would have to be made to increase capacity. If the government already funds on 
average two scans per pregnancy, one could question the relevance of the present analysis. 
However, this ignores the fact that the distribution of the scans among pregnant women and 
the exact timing is unknown. It may be plausible to assume that some women who test 
positive may decide to go for a second scan, “a second opinion” as it were, before deciding 
whether to proceed to follow-up diagnostic tests. The government could easily, if it were so 












system, but this could have negative ethical implications in terms of autonomy and equity of 
access. 
 
A move to routine scanning in the first trimester is nevertheless likely to have some 
consequences. According to Helbig (100), it may lead to extra referrals to specialist centres 
for foetal medicine since physicians and midwives may be uncertain as to the interpretation of 
the first trimester scan results. Svaasand (93) believes it will bring about different strategies 
with respect to diagnostic testing, with an emphasis on chorionic villus sampling rather than 
amniocentesis. There is however, limited evidence available on the effects on follow-up 
diagnostics of the extension of screening programmes. O’Connell et al. (101) published a 
review in 2006 of 11 retrospective cohort studies that examined the effect of screening on 
invasive testing. However, the studies were characterised as being “not high” in quality - the 
authors found that many of them had small sample sizes and low external validity, and none 
looked at changes in testing following the introduction of integrated or sequential screening 
methods. O’Connell observed that although there are a number of short-term studies available 
that evaluate screening for Down syndrome, they did not have a sufficiently long follow-up 
period to evaluate the long-term consequences with respect to invasive testing. However, the 
results from Ekelund et al. from Denmark (102) reveal that the extension of the screening 
programme in that country to one resembling the Combined strategy in the model, may 
actually have contributed to a significant reduction in the rate of follow-up testing. The Centre 
for Medical Genetics and Molecular Medicine at Haukeland University Hospital in Bergen, 
Norway (90) states in its 2005 annual report that the number of amniocenteses has gone 
down. The possible explanation is that the serum test which has been offered at the hospital 
for some time may have reduced – rather than increased – the need for invasive follow-up 
testing. No figures were found as to the frequency of chorionic villus sampling. A change in 
the form, rather than the overall volume, of invasive testing is in any event likely to have little 
consequence due to similar risk of miscarriage, and the cost differences are likely to be 
minimal. The evidence from Denmark and Bergen does however suggest that new studies on 
the effects of the first serum test on risk assessment and follow-up testing are warranted in 
Norway. 
Women’s preferences 
One may infer from the existence of a number of private health care providers offering 












such services in this country. Nilsson et al. (73) report that women, when asked, respond that 
they desire screening as early as possible in pregnancy and that they feel they need sufficient 
time to consider their options. Studies (15;103) show that a first trimester scan does not 
apparently lead to any rise in anxiety compared to a second trimester scan. However, the 
studies reveal that the level of anxiety does increase in women who are told they have a 
higher risk for foetal anomalies, and that this is not necessarily reduced as a result of being 
confirmed false positive. Women also express concern about the risk of miscarriage in 
relation to invasive testing. Reinar et al. (15) stress the need for appropriate methods of 
providing information to assist pregnant women in making decisions based on risk 
assessment. Some women and their partners may have difficulty in grasping the meaning of 
nuchal translucency measurement and soft markers, and that these provide an estimate of risk 
rather than a definitive answer (73;104). Parents can sometimes be unprepared for adverse 
findings (105) and may even view the scanning session as a form of entertainment – a chance 
to see the child for the first time (98). Although Nilsson et al. (73) suggests that women 
considered that they were responsible for the decisions related to ultrasound scanning, Forbes 
(98) is highly critical of what she considers to be excessive medical control with regard to 
antenatal screening. There is little evidence as to the preferences of Norwegian women 
regarding the actual screening process, but the number of scans has probably risen in recent 
years. Meanwhile, first-time mothers are getting older; their average age has increased from 
25.3 to 28.1 during the course of the 15 years preceding 2005 (106). The prevalence of 
congenital anomalies such as Down syndrome is therefore likely to have gone up, but the 
number of abortions has nevertheless remained stable (14). The number of late abortions 
(after week 12) has increased gradually from 0.44 per 1 000 women in 1999 to 0.58 in 2006, 
70% of which were carried out before week 18. The Medial Birth Registry cannot however, 
determine whether this trend can be ascribed to a higher frequency of scanning. 
 
Equity of access 
The routine ultrasound scan offered to Norwegian women in the second trimester is voluntary 
and – but for the co-payment charge  – free. The uptake was 97,5% in 1994 (97), and 
participation is likely to remain high, judged by the number of scans carried out in the public 
sector. However, there is a lack of recent survey data on the national level with regard to the 
socio-economic, geographic or ethnic background of women with regard to utilisation of 
ultrasound scans, which could be used to address the issue of equity of access. However, 












preliminary judgments with respect to geographic area. Norway is divided into four 
administrative health regions which are charged with offering specialist hospital services, 
including obstetric care to inhabitants. The dominant region, the South-eastern region, covers 
the densely populated area along the coastal stretch of southern Norway up to Oslo and its 
surrounding counties. More than half of all babies born in Norway in 2006 were delivered 
here, according to the figures (107) in the table below. Here, the rate is slightly higher than 
the national average of 2 scans per birth in the southeast. The rate is even higher in mid-
Norway, the regional capital of which is Trondheim, where St Olav’s Hospital, a renowned 
centre within the field of obstetrics and foetal medicine happens to be located, although no 
causality is implied. The lower than average rates are found in the two other regions, 
particularly in the sparsely populated and – in geographical terms – large Northern region – 
where for many, ultrasound facilities may be located miles away. For women living here, the 
offer of a first trimester scan could mean that they would have to make a long journey twice if 
the local hospital cannot provide such services. Such issues could however, to some extent be 
addressed by the use of telemedicine technology, especially with regard to anomalies such as 
serious congenital heart defects, as was demonstrated in a study from the UK (108) where 
scans for women in small towns in England were sent directly to perinatal cardiologists in 
London for detailed foetal echocardiography. 
 
Table 16 Number of births and abdominal  
ultrasound scans, 2006 
Regional Health 
 Authority 
Births Per cent Abdominal 
US scans 
Per cent Scans 
per birth 
South-eastern  31 421 56 66 471 59 2.12
Western  12 806 23 21 960 19 1.71
Mid-Norway  7 270 13 17 140 15 2.36
Northern  4 854 9 7 638 7 1.57
Total 56 351 100 113 209 100 2.01
Source: The Norwegian Medical Birth Registry, and The Directorate of Labour and Welfare, 2006 
 
In terms of the socio-economic status of those using ultrasound scans, research indicates 
(109;110) that utilisation may depend on socio-economic status and that screening uptake is 












large extent publicly funded in Norway, and income distribution in Norway is relatively 
equitable. Implementation of first trimester universal scanning could actually improve equity 
of access, since the present system requires a woman not classified as “high risk” either to 
have a private scan or a referral from a general practitioner on the grounds of “medical 
anxiety” if she desires a first trimester scan. The hypothesis can as yet not be substantiated by 
domestic studies, but it is plausible to assume that well-informed, resourceful women are 
more likely to take advantage of such opportunities than other women. The level of co-
payment, which would on average amount to NOK 560 per pregnancy, could provide a barrier 
to some groups, but there is an annual cap on co-payment for all public health services at 
around NOK 1 500 to ensure that low-income groups are not prevented from utilising 
services. In terms of ethnic minorities, Norway’s minority population has grown since 1994 
when the survey on uptake was carried out and little is known as to whether the attitudes 
towards antenatal screening amongst minority groups differ from that of the overall 
population. Studies from Australia (111) and the Netherlands (112) indicate that there may be 
some variation according to uptake between ethnic groups. In 2005, about 5.7% of the 
resident population were born in countries outside the OECD, with Pakistan supplying the 
highest number of immigrants (113). Again, there is a need for further research to examine 
whether the utilisation rates differ compared to the overall population. 
Ethical issues 
Whether the Norwegian government chooses to expand its antenatal screening programme to 
include first trimester scanning or not, its action – or lack of such – will carry ethical 
implications (104). If the government were to recommend screening in the first trimester it 
would have to justify the move either in terms of medical gain or a reduction in spending. The 
systematic review conducted by Reinar et al. (15) concludes that the gains from ultrasound 
screening in the first trimester were marginal with regard to the determination of term date, 
multiple pregnancies or serious structural malformations without chromosomal anomalies. 
There are however, as has also been demonstrated by the present study, gains in terms of the 
detection of cases of Down syndrome. Even though the rate of scanning would remain the 
same following a potential reorganisation of provision as noted in a previous section, publicly 
funded first trimester scanning could increase the attention on anomalies such as Down 
syndrome. Implementing the programme could therefore be seen as reinforcing the negative 
attitude towards this condition, affecting people living with Down syndrome, other handicaps 












done, both in the medical field and in society at large, to enable people with Down syndrome 
and other serious conditions to enjoy life to its full potential, and to be integrated as much as 
possible in society. Some may argue however, that the subtext of antenatal screening 
programmes is that such people are not really welcome. Alison Davis, who has spina bifida, 
puts it bluntly (114) “I strongly believe that it is not possible to have a positive attitude towards a 
minority group while one is simultaneously directly involved in their deliberate destruction.” The 
fact that pregnant women are willing to avoid giving birth to an affected foetus by undergoing 
invasive procedures that could endanger an unaffected foetus underlines the point. However, 
the higher detection rates associated with a first trimester strategy is likely to enhance the 
opportunity to prevent the birth of children with Down syndrome, as happened in Denmark. 
Following the introduction of a first trimester combined risk assessment strategy the number 
of children born with the condition was virtually halved in that country (102). Solberg (104) 
ascribes this to the majority of women having access to early ultrasound, rather than a change 
in personal preferences towards having a child with Down. As in the case of economic 
studies, much of the attention paid to the ethics of antenatal screening refers to Down 
syndrome. The ethical picture may be somewhat different with respect to serious congenital 
heart defects due to the low survival rate – it may be easier to justify the removal of a foetus 
who is highly likely to die relatively soon after birth.  
 
What if the government were to decide not to implement universal screening in the first 
trimester? The ethical impact of such a strategy would, according to Reinar et al. (15) be the 
following. Society would have to handle the costs arising from the birth of more children with 
anomalies or birth defects than would otherwise have been the case. It would further have to 
accept the potential burden for women who will have to bear an affected foetus for longer 
than “necessary” which involves more anxiety, or give birth to a child with an anomaly when 
this could have been avoided. Finally, it is suggested that to refrain from implementing first 
trimester universal scanning would be the same as to legitimise a limitation of the right of the 
individual to make choices in a private area in which real technological opportunities are 
offered. However, the availability of private screening implies that those who desire a first 
trimester scan would be able to have one if they could afford it. 
 
It could however, not be entirely unreasonable to postulate that whatever course of action the 
government decides to take the ethical impact would be limited. There are at least two reasons 












diagnostics in the guidelines for antenatal care of 2004 (104) women who do not necessarily 
fall into one of the defined risk groups may still request a scan for antenatal anomalies. One of 
the objectives of the Biotechnology Act of 2003 (17) was to avoid such cases, and an explicit 
distinction was made between genetic counselling and foetal diagnostics on the one side and 
routine ultrasound scanning on the  other. The Act was intended to provide a bulwark against 
the so-called “society of qualitative selection - sorteringssamfunnet” – which has become 
something of a catchphrase in Norway (104). The distinction between foetal diagnostics and 
routine ultrasound may however, be hard to observe in practice or even in theory, and Solberg 
(104) notes that experts in the field of medicine were quick to point out that the law would not 
have any effect. Regardless of government policy, women can today do more or less whatever 
they want as far as first trimester screening is concerned. The fact that first trimester screening 
is on offer in the private sector means that potential parents will not be barred from 
undertaking the scan, unless they cannot afford it. To decide whether or not to have children 
is not primarily a medical issue, it is rather a matter to self-determination and autonomy (104). 
If women desire information about their foetus, they should be allowed to receive it. 
Sometimes the information is unwanted (115) though there may be a perceived social pressure 
by the very existence of the test, as noted by Forbes in New Zealand (98), which may lead to 
feelings of guilt if it were not utilised. Williams (116) describes the role of women going 
through ultrasound scanning in the first trimester as “moral pioneers”, in that they may have 
to make tough moral decisions.  
 
Kvande (117) claims that the ethical debate surrounding obstetric ultrasound only surfaced in 
the 1990s and was largely suppressed in the first consensus conference on the issue in 1986. 
When it did arise, she argues, it was closely associated to the abortion issue and the 
development of technologies such as artificial insemination and so-called “designer babies” 
(118). Reinar et al. (15) argue that the ethics of antenatal screening has largely been left to the 
individual or to professional ethicists and that two fundamental values have not been 
questioned in the debate: Women’s right to choose abortion until the 12h week of gestation 
and the desire for a society where there is room for everyone. Hviid-Nilsen (119) calls the 
conflict between individual and collective desires the “state liberal dilemma” and compares it 
to Adam Smith’s theory of the invisible hand. In Smith’s theory, the sum of individual actions 
driven by self-interest served to benefit society as a whole. In the “state liberal dilemma” 
however, the sum of individual actions has an aggregate negative impact. Moreover 












a situation where the state may sanction, even facilitate, the choices that collectively may 




The results presented in the previous chapter are those of a cost-effectiveness analysis where 
the outcome measure is the number of cases detected. For reasons outlined in the literature 
review, this is perhaps the most practical and straightforward approach with regard to 
examining the consequences of antenatal screening. However, this may also be the prime 
deficiency of this analysis. Though the point shall not be reiterated at length here, the 
literature review showed that detection might be associated with an economic value in itself, 
regardless of any subsequent action. Due to lack of data, the analysis cannot ascribe any such 
value to detection, and thus assist policymakers in determining whether this activity is 
worthwhile to extend in relation to other activities demanding resources within the health 
sector or in society as a whole. Further, the model only examines the number of anomalies 
found. Any advantages and disadvantages associated with the process of screening and 
diagnostic testing such as reassurance, anxiety and iatrogenic miscarriage are, in terms of their 
economic value, ignored. The same applies to any benefits that may be derived from the use 
of ultrasound in foetal medicine that could affect the health of the foetus or the mother. Again, 
as pointed out in the literature review, for all consequences to be compiled and valued, a cost-
benefit or cost-utility analysis would have to be carried out. Such exercises would require data 
on either the Norwegian population’s willingness to pay for - or the quality of life associated 
with – antenatal screening, which are currently unavailable. 
 
The focus on anomalies may, given these constraints, not be entirely unreasonable. It is 
nevertheless restricted to covering only two. The original objective of this study, as stated in 
the protocol, was to include other anomalies in addition to Down syndrome and serious 
congenital heart disease. Effectiveness data on other anomalies were searched for, but it was 
difficult to find evidence that could be employed in the model. Either data were missing for 
both the first and second trimester, or the sample size in the efficacy study was too small. 
Moreover, the anomaly could be defined too broad in nature for the purpose of this study. An 
example of the latter is Saltvedt’s study from 2006 (120), which looked at structural 












their definition of structural anomaly. Nevertheless, the fact that the model comprises only 
two anomalies means that the results in terms of cost per anomaly detected and the difference 
in anomalies detected between the Current and the two other strategies may be somewhat 
distorted.  
Efficacy data 
Given the rapid technological development in this particular field, the efficacy data used in 
the model are relatively old. The actual sensitivity and specificity of the ultrasound scans used 
in Norwegian obstetrical clinics in 2006 may thus differ from those observed in the trials due 
to variations in standards of equipment. Even though the efficacy studies were picked out on 
the basis of geographic and chronological proximity, the skills level of the ultrasound 
operators could also deviate from that seen in clinical practice in 2006. This factor may have a 
significant impact on the outcome of the scan, according to Tegnander (71). Although the 
average age of the pregnant population has bearings on the risk for congenital anomalies, the 
data used have only been classified as “unselected” or “high risk”. The high-risk data used 
may not necessarily reflect the characteristics of the Norwegian group of women over the age 
of 38 or with a family history of congenital anomalies offered ultrasound in the first trimester 
as part of a system of foetal diagnostics.  
 
The efficacy data used in the model are geared at measuring the number of cases that can be 
found of a single anomaly in either the first or second trimester, and are thus independent of 
each other, when in fact a population which has already been screened should be more “low-
risk” than one which has not. However, the prevalence rate has been adjusted in the second 
trimester in the model to minimise the potential problems this could have caused. On the other 
hand, the model permits the detection of only one anomaly at a time, i.e. a case is labelled as 
either one with Down syndrome or serious congenital heart defects, when the two can in fact 
sometimes be linked to each other (1). 
Costing 
Except for the calculations of costs related to productivity loss, the costs used in the model are 
all based on tariffs. There are a number of drawbacks associated with this approach, since 
tariffs do not necessarily represent the opportunity costs of scarce resources. To elicit such 
costs in the context of antenatal screening, one should take account of the capital costs of the 












devoted to screening and diagnostic activities as well as a proportion of overhead costs to 
account of running costs and administration expenses (46). Such a task would however, be too 
time-consuming for the present study. Most of Norway’s hospitals are state owned, but 
funding in 2006 was channelled through two sources, either directly through the Ministry of 
Health or indirectly via reimbursement tariffs from the National Insurance Administration. 
Outpatient activities were financed through the latter channel, and tariffs may thus be a useful 
proxy for costs in this area, provided that changes in the activity in question do not require 
major investments in buildings, capital or training. Nevertheless, the fact that the National 
Insurance Administration tariffs B20c and B20h - denoting routine abdominal or transvaginal 
ultrasound and counselling associated with antenatal diagnostics respectively - are perfectly 
identical, there is grounds for concern as to whether the tariffs are fully representative of the 
costs they intend to cover. 
 
The use of market prices is a pragmatic attempt at mirroring the opportunity cost of 
production (46). Although it may be argued that the market for ultrasound scanning is not 
perfect due to factors such as asymmetry of information, it may be worthwhile to compare the 
prices advertised by ultrasound providers in the private sector to the tariffs used by public 
hospitals (46). It should be noted however, that private operators only seldom offer follow-up 
diagnostics and high-risk individuals tend to be referred to the public sector. A small, 
informal survey amongst private providers in Oslo revealed some variation in cost as seen in 
the table below. The prices are all more than 3 times the size of the National Insurance 
Administration tariff. Since the financing of outpatient services in public hospitals in Norway 
is only partly activity or tariff based, but also involves lump sum transfers, such services are 
in effect subsidized. It is therefore likely that the analysis of “full direct costs” described in 
the sensitivity analysis section of the last chapter would be closer to actual costs of ultrasound 
scanning in the public sector. 
 
Table 17 Cost per ultrasound scan in the private sector, 2009-prices 
Provider Cost per scan, NOK Comment 
Ultralydklinikken (The 
Ultrasound Clinic) 900
3D ultrasound, operator not stated, includes 
DVD 
Helsepartner (Health Partner) 700
Technology standard not known, scan 
conducted by paediatrician or radiologist 
Volvat Medical Centre 1040
Technology standard not known, scan 













The issue of uncertainty surrounding the valuation of productivity loss in the calculation of 
indirect costs was raised in the last chapter. The time women spend away from work in the 
model is assumed to be the bare minimum. However, their partners might also take time off to 
accompany them. The parents might not be employed in paid work, but it is reasonable to 
assign some value to time, which could be spent in educational or leisure activities. Bricker et 
al.(67) have followed such an approach, but used a lower value for the non-work activities. 
This could not be done in the present model due to the lack of statistics on the daily activities 
of Norwegian pregnant women. 
Model structure 
The main advantage of the model structure is that it facilitates the overall probability of being 
found positive in the first stage of screening, while the detection rates of individual conditions 
may be presented separately in the results. It could easily be adapted to fit other types of 
screening tests where it is possible to detect several diseases based on one test, for example a 
blood or urine sample. However, certain assumptions may often have to be made to prevent 
the model from becoming too complex. There are two examples of such assumptions that 
could contribute to uncertainty regarding the results. The first relates to the modelling of 
follow-up diagnostics. As mentioned in the Results chapter, this is uniform across both 
anomalies and trimesters covered in the model. Although it is not possible to ascertain 
precisely the proportion of those testing positive for either anomaly that will proceed to 
follow-up testing, it seems intuitively reasonable to expect that the number for serious 
congenital heart disease is higher than that for Down syndromes. Moreover, the model 
suggests that if there were a 100% rate of follow-up, then some seven thousand amniocenteses 
would be conducted in Norway as a consequence of routine ultrasound scanning in the second 
trimester. The actual figure was 1100 in 2006. The reason for the disparity between the model 
and clinical practice could be one or more of the following: There are fewer women testing 
positive in the second trimester, the rate of follow-up in practice must be relatively low and 
that women testing positive may prefer another ultrasound scan rather than be confirmed by 
amniocentesis. The second element, somewhat linked to the first, concerns the modelling or 
rather lack of modelling of abortions – not the ones that occur as a consequence of antenatal 
screening, but rather prior to it. According to Svaasand (93), miscarriage takes place in 50% 
of all pregnancies with Down syndrome. As already mentioned this implies that the number of 












Leporrier however,(121) observes that detected cases of Down syndrome are more likely to 
be spontaneously aborted than undetected ones and since the model’s outcome measure is 
detection, then the potential error might be reduced. Apart from reducing the number of 
potential scans, miscarriage or abortion would have an impact on the cost estimation in the 
model to the extent that it took place at a point between testing positive and follow-up 














Summary of main findings  
In 2006, the Government of Norway, via its Directorate of Health and Social Affairs, decided 
to investigate the consequences of a change in its policy with regard to the funding and 
provision of routine ultrasound scanning for pregnant women. The strategies that were to be 
specifically considered were two which included first trimester ultrasound scanning with 
nuchal translucency – with and without a serum test – in addition to the universal scan 
provided in the second trimester. The present study has considered the economic aspects of 
the proposed change, focusing on two serious congenital anomalies: Down syndrome and 
serious congenital heart defects, whilst acknowledging that there are other important 
outcomes which have not been captured in the analysis. The complex nature of antenatal 
screening and the many methodological challenges associated with economic evaluation in 
this field meant that a cost-effectiveness analysis was considered to be the most pragmatic and 
feasible approach. A cohort of 60 000 annual pregnancies was modelled in a decision tree, of 
which 5 000 were assigned to the so-called “high risk” group. 
 
The primary objective of this analysis was to calculate the incremental cost-effectiveness in 
terms of cost per additional anomaly detected, from both the health care and societal 
perspective. It was found that incorporating first trimester universal ultrasound scanning 
enabled the number of total cases detected to increase by approximately 33% from 468 in the 
Current strategy to 620 in the Comprehensive strategy and 625 in the Combined strategy. The 
direct costs per additional case detected in the two first trimester universal scanning strategies 
were approximately NOK 218 000 (Comprehensive) and NOK 230 000, (Combined) while 
the total (direct + indirect) costs were approximately NOK 350 000 (Comprehensive) and 
NOK 398 000 (Combined). The Comprehensive strategy may be considered to be the most 
cost-effective of the two proposed first trimester universal scanning strategies, though the 
Combined strategy generates a few extra detected cases. In terms of average costs however, 
the Current strategy appears to be the most cost-effective choice with approximately NOK 71 
thousand per case detected. An analysis of the breakdown of the extra cases detected showed 
that 77 (Comprehensive) and 82 (Combined) were cases of Down syndrome, whereas the 












approximately two thirds of the potential number of Down syndrome cases and about a 
quarter of the cases of serious congenital heart defects. 
 
The secondary objective was to estimate the costs of the Current strategy, which was 
measured on the basis of 2006 tariffs (direct costs) and productivity loss (indirect costs). The 
direct costs were estimated to be NOK 33.2 million, while the total costs (direct + indirect 
costs) were NOK 68.8 million. 
 
The number of cases confirmed as false positive rose by approximately 9% in the two first 
trimester universal scanning strategies. The sensitivity analyses showed that the rate of 
participation in follow-up diagnostic testing has a significant bearing on the results: Almost 
all Down syndrome cases could be found if the rate were 100%, and almost half of all cases of 
serious congenital heart defects. Increasing the rate of invasive testing however, is liable to 
cause a rise in the number of miscarriages. 
 
Policy recommendations 
It should be stressed that no decision with respect to extending the antenatal screening 
programme should be taken on the basis of economics alone, as there are significant ethical 
implications. Moreover, there is as yet no consensus as to how economic evaluations are to be 
interpreted. Outpatient services in public hospitals cost 6 481 million kroner in 2006 (122). 
Had a cost-benefit analysis been available, it might have shown that it would have been more 
sensible to spend the extra 33-36 million kroner on other health interventions, or even on 
programmes in other sectors, but no such analysis is available.  
 
There are however, arguments in favour of a publicly financed first trimester universal 
scanning programme not necessarily related to the number of detected cases:  
 
Resource planning: The private sector performs ultrasound scanning in the first trimester, 
but does not assume responsibility for follow-up diagnostic testing or counselling of those 
who test positive. These are referred to specialists in the public sector. In addition, statistics 
show that the public sector already funds on average 2 scans per pregnancy. If all pregnant 
women are offered a first trimester scan, early risk assessment may ensure that appropriate 












routine antenatal screening programme could reduce the extra expenditure associated with a 
first-trimester universal scanning component.  
 
Women’s preferences: Evidence from the literature and the emergence of private sector first 
trimester scanning provision suggest that women desire antenatal screening as early as 
possible in pregnancy, but they also demand appropriate information regarding how the scans 
are to be interpreted and the characteristics of follow-up testing. 
 
Equity: First trimester scanning is privately offered to those who can afford it both within and 
outside Norway. The current system also enables women who are not strictly categorized as 
high risk to be referred to ultrasound scanning on the basis of pregnancy-related anxiety. 
Resourceful women might lobby their GP for such referrals, whereas less-informed women 
might not. A publicly financed first trimester universal scanning scheme would lower the 
potential barriers to access. 
 
All other things equal, detection early seems intuitively to be better than detection late. The 
model shows that the Comprehensive strategy is the more cost-effective of the two proposed 
strategies, and is therefore the one that should be considered implemented first. There is 
however, some uncertainty as to the role of the serum test with regard to the need for follow-
up testing, which should be investigated further.  
 
The experience from Denmark and elsewhere suggests that increasing the role of the 
government in early antenatal screening can be interpreted as sanctioning a “qualitative 
selective society”. This is an issue not uniquely related to ultrasound screening, given the 
rapid development of other types of foetal diagnostics and the technology related to artificial 
insemination. However, it is recommended that the Government attempts to stress that a 
handicapped child should be as welcome as any other and can provide a valuable contribution 
to society. Perfection is not necessarily worth striving for. 
 
Recommendations for further research 
The economic literature on antenatal ultrasound screening shows that there is a great variation 
in cost estimates. It is therefore difficult to compare study results, even from the same 












Women’s Hospital in the United Kingdom (123), and it is recommended that one be carried 
out in a representative hospital in this country to reveal the actual costs of ultrasound scanning 
and follow-up diagnostic tests. Furthermore, statistics should be collected as to the frequency 
and timing of ultrasound scanning among pregnant women. Combined, this information could 
be used to rationalise the public sector antenatal screening programme.  
 
As to the need for further economic evaluation, this study has shown that there are challenges 
with regard to capturing all the potential positive and negative effects of ultrasound screening. 
The type of economic evaluation that could potentially capture all the dimensions of an 
antenatal screening programme is the cost-benefit analysis, though there are challenges with 
regard to its design and execution. A survey of willingness-to-pay for proposed strategies 
would have to be developed, but for such an analysis to be feasible, information should be 
made available as to what the consequences of different strategies would be in terms of how 
the detection and false positive rates at different stages in pregnancy and what this means to 
an average pregnant woman. The reason for this is that the willingness-to-pay may vary 
depending on not only on how many, but also what types of anomalies can be detected – 
lethal, a treatable condition or one involving long term morbidity. More information and 
transparency with regard to antenatal screening would be a good thing whether or not is to be 
used for an economic analysis. The co-ordinating role and information provided, both to the 
public, health personnel and researchers, by the United Kingdom’s NHS Fetal Anomaly 
Ultrasound Screening Programme on its website (124) could provide a useful model. 
Moreover, since there seems to be no consensus as to the type of analysis best suited for 
antenatal screening and how it is to be interpreted, it is recommended that one ought to be 
found: Health economists and clinicians could set up a working group in order to propose a 
reference case, as, for example, done for economic evaluations of rheumatoid arthritis 
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Figure A4 Entire model 
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